[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1422
1. Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang SX, Okayasu I: Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer; 2010 Jul;69(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the utility of KU-Lu-3, we immunohistochemically studied 184 cases of pulmonary carcinoma and paired normal lung tissues, using formalin-fixed and paraffin-embedded tissue microarray sections.
  • Moreover, RACK1 expression was also significantly associated with the pathological stage, tumor size and lymph node status of adenocarcinoma patients, but not with tumor differentiation, or patient age and gender.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. GTP-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal. Diagnosis, Differential. Early Diagnosis. Female. Humans. Hybridomas. Immunohistochemistry. Lung / immunology. Lung / metabolism. Lung / pathology. Lymphatic Metastasis. Male. Microarray Analysis. Middle Aged. Neoplasm Staging. Tumor Burden

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19892429.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / GNB2L1 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; EC 3.6.1.- / GTP-Binding Proteins
  •  go-up   go-down


2. Wei WD, Wen ZS, Su XD, Lin P, Rong TH, Chen LK: [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection]. Ai Zheng; 2007 Nov;26(11):1231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
  • BACKGROUND & OBJECTIVE: Multi-disciplinary management for non-small cell lung cancer (NSCLC) has been applied for more than ten years.
  • The 5-year survival rates were 81.0% for the patients at stage IA, 60.3% for stage IB, 56.9% for stage IIA, 45.7% for stage IIB, 23.5% for stage IIIA, 20.8% for stage IIIB, and 13.0% for stage IV.
  • Univariate analysis showed that T stage, N stage, M stage, histological type, differentiation, chemotherapy for adenocarcinoma (ADC) at stages II and IV, and mediastinal radiotherapy for ADC at stage N2 were prognostic factors.
  • Multivariate analyses showed that histological type, T stage, N stage, M stage and mediastinal radiotherapy for ADC at stage N2 were independent prognostic factors.
  • CONCLUSION: Besides T stage, N stage, and M stage, histological type and mediastinal radiotherapy for ADC at stage N2 are also independent prognostic factors of NSCLC after complete resection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods


3. Biswas S, Sarkar S, Chakraborty J, Chakrabarti S: Occult micrometastasis to bone marrow in early lung cancer: a clinicopathologic study from West Bengal, India. Asian Pac J Cancer Prev; 2010;11(3):747-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult micrometastasis to bone marrow in early lung cancer: a clinicopathologic study from West Bengal, India.
  • Although bone marrow micrometastasis may remain silent, its detection changes the staging and management of lung cancer.
  • In the present study conducted in West Bengal, India, 74 diagnosed bronchogenic carcinoma cases (28 squamous cell carcinomas, 20 adenocarcinomas, 9 small cell carcinomas, 4 large cell carcinomas, 13 unclassified) in early stages (stage I, II and IIIA) were included.
  • We detected marrow metastasis in 44.4% cases of small cell carcinomas and 21.2% cases of non small cell lung cancer (50% of large cell carcinomas, 20% of adenocarcinomas, 17.9% of squamous cell carcinomas) and 15.4% cases of unclassified carcinoma.
  • A definite correlation noted between micrometastasis with the clinical stage (no case in Stage I, 12.5% in Stage II, 30.4% in Stage IIIA patients).
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Neoplasms / secondary. Carcinoma, Large Cell / secondary. Carcinoma, Small Cell / secondary. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology


Advertisement
4. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS: Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1037-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
  • PURPOSE: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy.
  • METHODS AND MATERIALS: Eligibility included inoperable clinical Stage III NSCLC without pleural effusion, ECOG performance status 0-1, and weight loss < or =5%.
  • The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others.
  • CONCLUSIONS: Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin showed very promising survival in patients with Stage III NSCLC, especially in those without supraclavicular nodal involvement, which warrants further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024178.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


5. Chen ZJ, Le HB, Zhang YK, Qian LY, Li WD: Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J Int Med Res; 2009 Mar-Apr;37(2):551-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features.
  • Microvessel density and thrombospondin-1 (TSP-1) expression were analysed in 42 non-small cell lung cancer (NSCLC) specimens and 40 normal lung tissue specimens using immunohistochemistry.
  • Significantly lower levels of TSP-1 expression and higher microvessel densities were found in late-stage NSCLC compared with early-stage NSCLC, and in those with lymph node metastasis compared with those without metastasis.
  • A statistically significant inverse correlation was observed between TSP-1 expression and microvessel density in squamous cell carcinoma but not in adenocarcinoma.
  • The lack of correlation between microvessel density and TSP-1 expression in adenocarcinoma suggests that the mechanism of tumour inhibition by TSP-1 varies according to histological type.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / blood supply. Lung Neoplasms / metabolism. Microvessels / pathology. Thrombospondin 1 / metabolism


6. Chatterji B, Borlak J: Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers. Proteomics; 2007 Nov;7(21):3980-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers.
  • We previously reported a proteome map of lung adenocarcinomas in serine-threonine kinase of the Raf family (c-raf) transgenic mice.
  • We now extend our initial studies to serum proteins at early stage (1 month) and advanced stages of tumorigenesis (12 months).
  • Notably, serum proteins from wild-type and tumor bearing mice were extracted with a lysis buffer containing 5 mol/L urea, 2 mol/L thiourea, 40 mmol/L Tris, 4% CHAPS, 100 mmol/L DTT, 0.5% BioLyte 3-10, separated by 2-DE and studied by image analysis.
  • Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of lung tumor bearing mice.
  • Thus, an identification of regulated serum proteins in this lung cancer disease model provides excellent opportunities for the search of novel biomarkers.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / genetics. Biomarkers, Tumor / blood. Lung Neoplasms / blood. Lung Neoplasms / genetics. Proto-Oncogene Proteins c-raf / genetics


7. Takakuwa O, Oguri T, Sato S, Nakao M, Ohta C, Iwashima Y, Miyazaki M, Maeno K, Kutsuna T, Nakamura A, Ueda R: [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1721-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
  • There is at present no defined role for S-1 chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who previously failed chemotherapy.
  • A 75-year-old man was diagnosed as having pulmonary adenocarcinoma, cT1N3M0, stage III B.
  • A 65-year-old woman was referred for treatment of recurrent pulmonary adenocarcinoma after right upper lobe resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use


8. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J: PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer; 2010 Apr 1;126(7):1630-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
  • The primary objective of this study is to identify prognostic site-specific epigenetic changes in surgically treated Stage I and II nonsmall cell lung cancer (NSCLC) patients by quantifying methylation levels at multiple CpG sites within each gene promoter.
  • Paraffin-embedded tumors from stage Ib, IIa and IIb in training and validation groups of 75 and 57 surgically treated NSCLC patients, respectively, were analyzed for p16, MGMT, RASSF1, RASSF5, CDH1, LET7, DAPK and PTEN promoter hypermethylation.
  • Methylation levels of the p16 promoter were significantly higher in squamous cell carcinoma than in adenocarcinoma (p = 0.020).
  • These results show that methylation of specific promoter CpG sites in PTEN, RASSF1 and DAPK is associated with outcome in early stage surgically treated NSCLC.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Lung Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Cadherins / genetics. Case-Control Studies. CpG Islands. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Death-Associated Protein Kinases. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lung / metabolism. Lung / pathology. Male. Middle Aged. Monomeric GTP-Binding Proteins / genetics. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local / genetics. Neoplasm Staging. Prognosis. Promoter Regions, Genetic / genetics. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795445.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH1 protein, human; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RASSF1 protein, human; 0 / RASSF5 protein, human; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


9. Oketa R: Survival of pulmonary cancer patients treated surgically. Prilozi; 2010;31(2):95-113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study is to investigate the survival of patients treated surgically for lung cancer.
  • The histological type was: 80 (53%) Squamous-cell carcinoma, 27 (17.9%) adenocarcinoma, 10 (6.6%) bronchioalveolar carcinoma, 5 (3.3%) small-cell carcinoma, and others--29 (19.2%).
  • The post-surgical stage was often advanced; 92 (63%) of the patients were at stage IIIA.
  • Survival was highly significantly better in patients with an early stage of the disease.
  • There are significant differences in survival (p<0.05) in relation to diagnosis, group-age, histology, and highly significant differences (p<0.01) regarding definition N, M, stage of disease, FEV1.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21258281.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Chen KY, Lee YC, Lai JM, Chang YL, Lee YC, Yu CJ, Huang CY, Yang PC: Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer. Eur J Cancer; 2007 Mar;43(4):782-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer.
  • To find novel prognostic factors, we used the expression profile of a poor prognostic factor of lung cancer, survivin (BIRC5), as a template to search for and compare transcriptome expression profiles in a lung adenocarcinoma microarray dataset.
  • The trophinin expression in lung cancer specimens was examined by immunohistochemical staining.
  • For stage I lung adenocarcinoma, the patients without trophinin expression had a better overall and disease-free survival.
  • Through a combination of data mining and biochemical assays, we identified trophinin, which could enhance cell invasion, as a novel prognostic factor for early stage lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Lung Neoplasms / diagnosis. Microtubule-Associated Proteins / metabolism. Neoplasm Invasiveness / diagnosis. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17254769.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / TRO protein, human
  •  go-up   go-down


11. Jo DH, Cheung DY, Kim HK, Son DK, Chung JS, Kim JI, Park SH, Han JY, Kim JK, Chung KW: [Small bowel metastasis from breast cancer: a case report]. Korean J Gastroenterol; 2005 Aug;46(2):137-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is a common malignancy in women and frequently metastasizes to various organs such as liver, lung, brain, bone and so on.
  • She was diagnosed as right breast cancer in stage I, received modified radical mastectomy 6 years ago and had been followed up without any evidence of residual disease.
  • The histology of the tissue taken from small bowel mass was adenocarcinoma, poorly differentiated.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Intestinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118525.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


12. Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM, Sharma S: CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer; 2006 Apr 10;94(7):1029-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL19 reduces tumour burden in a model of advanced lung cancer.
  • To mimic therapy in late-stage disease, 3-month-old transgenic mice were treated with recombinant CCL19 (0.5 microg dose(-1)) by intranodal (axillary lymph node region) injection three times per week for 4 weeks.
  • Lung tissue cytokine profiles showed a shift towards immune stimulatory molecules with a decrease in the immunosuppressive cytokine TGF-beta.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2000 Jan 1;11(1):53-65 [10646639.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3205-13 [16540672.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):4025-31 [10754294.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6406-12 [11522634.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):202-6 [12000861.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6457-65 [14662845.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2891-901 [15102698.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):265-72 [8426105.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1057-65 [8350046.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1223-30 [8104230.001]
  • [Cites] Science. 1994 May 13;264(5161):961-5 [7513904.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):600-8 [8600310.001]
  • [Cites] Nat Med. 1996 Oct;2(10):1096-103 [8837607.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):981-92 [9064358.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] J Leukoc Biol. 1997 Mar;61(3):246-57 [9060447.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2635-43 [9108380.001]
  • [Cites] Annu Rev Immunol. 1997;15:675-705 [9143704.001]
  • [Cites] J Immunol. 1997 Jul 15;159(2):770-6 [9218594.001]
  • [Cites] J Leukoc Biol. 1997 Oct;62(4):450-7 [9335314.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2418-24 [9498785.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1208-16 [9515807.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4434-43 [9616136.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):181-91 [9653094.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):927-32 [9670971.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):373-86 [9670049.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2580-5 [9725259.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3033-41 [9743368.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):483-90 [9815709.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell Immunol. 1999 May 1;193(2):226-35 [10222066.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):537-47 [10433946.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):5020-8 [10528207.001]
  • [Cites] J Immunother. 2005 Mar-Apr;28(2):120-8 [15725955.001]
  • [Cites] Immunity. 2005 Apr;22(4):493-505 [15845453.001]
  • [Cites] Nat Med. 2000 Mar;6(3):332-6 [10700237.001]
  • (PMID = 16598185.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090388; United States / NCI NIH HHS / CA / R01 CA085686; United States / NCI NIH HHS / CA / P50 CA90388; United States / NCI NIH HHS / CA / R01 CA85686
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ccl19 protein, mouse; 0 / Chemokine CCL19; 0 / Chemokines, CC
  • [Other-IDs] NLM/ PMC2361223
  •  go-up   go-down


13. Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL: Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One; 2010 Aug 17;5(8):e12222
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.
  • BACKGROUND: Lung cancer remains the leading cause of cancer-related deaths worldwide.
  • The recurrence rate ranges from 35-50% among early stage non-small cell lung cancer patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: From genome-wide mRNA expression profiles generated on 256 lung adenocarcinoma patients, a 12-gene signature was identified using combinatorial gene selection methods, and a risk score algorithm was developed with Naïve Bayes.
  • This gene signature also stratifies stage I and IB lung adenocarcinoma patients into two distinct survival groups (log-rank P<0.04).
  • The 12-gene risk score is more significant (hazard ratio = 4.19, 95% CI: [2.08, 8.46]) than other commonly used clinical factors except tumor stage (III vs. I) in multivariate Cox analyses.
  • The 12-gene model is more accurate than previously published lung cancer gene signatures on the same datasets.
  • The identified 12 genes exhibit curated interactions with major lung cancer signaling hallmarks in functional pathway analysis.
  • With this 12-gene risk score algorithm, early stage patients at high risk for tumor recurrence could be identified for adjuvant chemotherapy; whereas stage I and II patients at low risk could be spared the toxic side effects of chemotherapeutic drugs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):882-90 [15105181.001]
  • [Cites] Science. 2004 Oct 22;306(5696):640-3 [15499008.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Sep;96(3):440-7 [2842549.001]
  • [Cites] Stat Med. 1998 Nov 30;17(22):2563-78 [9839348.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Sep 15;172(6):729-37 [15976377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Science. 2006 May 26;312(5777):1165-8 [16728629.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4583-9 [16899605.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2606-12 [17088437.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):820-32 [17339364.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5562-9 [18065728.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):107-15 [19082483.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8213-20 [19088038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8 [19196983.001]
  • [Cites] J Natl Cancer Inst. 2010 Apr 7;102(7):464-74 [20233996.001]
  • (PMID = 20808922.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016440; United States / NLM NIH HHS / LM / R01 LM009500; United States / PHS HHS / / NIH/NCRR P2016477; United States / NCRR NIH HHS / RR / P20 RR016477; United States / NCRR NIH HHS / RR / P20RR16440; United States / NLM NIH HHS / LM / R01LM009500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2923187
  •  go-up   go-down


14. Takagi K, Takahashi S, Hata Y, Tamaki K, Kato N, Sasamoto S: Use of emergency rigid bronchoscopy to reduce tumour mass prior to surgical resection. Respirology; 2007 Sep;12(5):777-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients with lung adenocarcinoma developed acute respiratory failure as a result of unilateral lung collapse.
  • They were successfully treated by tumour de-bulking using a rigid brochoscope and subsequent radical sleeve lobectomy.
  • Case 1 was a 46-year-old man whose carcinoma was pathological stage IIIb (P-T4N2M0), and he remains tumour-free 39 months after the surgery.
  • Case 2 was a 79-year-old man whose carcinoma was pathological stage IIb (P-T3N0M0).
  • Debulking of tumours with a rigid bronchoscope was useful for improving patients' quality of life and for the subsequent multidisciplinary treatment of lung carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Bronchoscopy. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875072.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE: Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res; 2009 Jun;15(2):173-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
  • FAK expression was assessed immunohistochemically in tumoral samples of 66 gastric adenocarcinoma cases, 30 intestinal and 36 diffuse type, and was statistically analyzed in relation to various clinicopathological characteristics, tumor proliferative capacity and patients' survival.
  • In diffuse type carcinomas, FAK staining intensity was significantly correlated with tumor size (P = 0.026) and disease stage (P = 0.024), presenting also a borderline association with nodal status (P = 0.053).
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Intestinal Neoplasms / enzymology. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] Oncology. 2006;71(5-6):417-22 [17687194.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19031-4 [1382065.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3272-9 [16740747.001]
  • [Cites] Toxicology. 2008 Mar 12;245(1-2):1-10 [18215454.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):571-4 [12943621.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30455-62 [9374537.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2812-7 [15102689.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1087-95 [15466376.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 [8832401.001]
  • [Cites] Histol Histopathol. 2008 May;23 (5):629-50 [18283648.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 23:4221-30 [11069767.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R194-203 [15743500.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2752-5 [7796399.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2417-23 [10873094.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):135-41 [3709818.001]
  • [Cites] Histochem Cell Biol. 1996 Jan;105(1):17-25 [8824902.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):359-74 [12884911.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2476-83 [16638855.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):686-90 [16521179.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):365-71 [9520949.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):413-8 [9052982.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12 ):2724-32 [16998832.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1315-28 [17907961.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):35-52 [16823799.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):613-8 [12174366.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(4):618-27 [10092214.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1728-34 [17932753.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2513-24 [11971186.001]
  • [Cites] Lung Cancer. 1997 May;17(1):69-84 [9194028.001]
  • [Cites] World J Surg. 2006 Feb;30(2):219-26 [16425085.001]
  • [Cites] J Cell Biol. 1992 Nov;119(4):905-12 [1385445.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Oct;5(5):415-20 [15544489.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):208-15 [17462972.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30597-604 [10899173.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):104-11 [15246215.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):140-5 [12838315.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):263-71 [16842883.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1289-94 [15861214.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 18987997.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


16. Gao YS, Zhang DC, He J, Sun KL, Zhang DW, Zhang RG: [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for stage I non-small-cell lung cancer].
  • OBJECTIVE: To evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
  • METHODS: The survival of 274 stage I NSCLC patients who underwent surgery from 1991 to 1998 were statistically analyzed by the Kaplan-Meier method.
  • RESULTS: The overall 1-, 3-, 5-year survival rates for patients with pathologic stage I lesion were 92.9%, 79.6% and 66.1%.
  • The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively.
  • The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05).
  • The 1-, 3-, 5-year survival rates of regular lobectomy were 94.1%, 79.3%, 67.5% and of conservative resection (segmentectomy and wedge resection) were 76.5%, 50.0%, 38.3% (P < 0.05).
  • CONCLUSION: The 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%.
  • The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%).
  • Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Fong Y, Lin YS, Liou CP, Li CF, Tzeng CC: Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology; 2010 May;15(4):700-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.
  • BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinomas of Asian patients, implying a good response to treatment with the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib.
  • However, the distinct chromosomal imbalances between lung adenocarcinomas with and those without EGFR mutations have not been fully elucidated.
  • METHODS: Seventy-seven patients of surgically resected lung adenocarcinoma were analysed for the EGFR exon 19 deletion and the L858R mutation, using mutant-enriched PCR, and for chromosomal imbalance alterations using comparative genomic hybridization.
  • The minimal regions with gain on 1q23-q31, 6p12-p21.1 and 7q11.2, and loss on 3p21, 8p22-p23, 9q33, 10q25 and 13q13, differed significantly between lung adenocarcinomas with or without EGFR mutations.
  • However, neither EGFR mutations, nor any of the common chromosomal imbalance alterations alone, exhibited significant associations with tumour stage or disease-specific survival of the patients.
  • CONCLUSIONS: These results indicate that imbalance alterations at several chromosomal regions occur significantly more frequently in lung adenocarcinomas with EGFR mutations than in those without such mutations.
  • Tumour growth-related genes in these chromosomal regions should be further investigated to improve our understanding of the common genetic alterations in lung adenocarcinomas with EGFR mutations.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Chromosome Aberrations. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409020.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


18. Yamato Y, Koike T, Yoshiya K, Shinohara H, Toyabe S: Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg Today; 2008;38(2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung.
  • METHODS: We retrospectively reviewed 523 cases of cT1N0M0 peripheral adenocarcinoma measuring 2 cm or less on diagnostic images treated by a complete resection between 1991 and 2004.
  • Univariate and multivariate analyses identified an older age, male sex, wedge resection, advanced stage, and Noguchi classification of C, D, E, or F as independent prognostic factors that adversely affected overall survival.
  • However, there were no significant differences in the survival according to surgical procedure in the patients whose tumors had a maximum diameter of 1.0 cm or less or in Noguchi type A and B cases.
  • CONCLUSIONS: Age, sex, surgical procedure, p-stage, and Noguchi classification were independent prognostic factors for survival in patients with small adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):988-93 [16678580.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Apr;125(4):924-8 [12698157.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):971-4 [11269483.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Aug;116(2):276-80 [9699580.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1033-7 [15756281.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):535-41 [12879471.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jun;111(6):1125-34 [8642812.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93 [15632829.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):769-75 [17000286.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Nov;20(5):1007-11 [11675189.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 May;115(5):1015-20 [9605069.001]
  • [Cites] Lancet. 1998 Apr 25;351(9111):1242-5 [9643744.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):956-60; discussion 961 [11269480.001]
  • (PMID = 18239866.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Haraguchi N, Satoh H, Kikuchi N, Kagohashi K, Ishikawa H, Ohtsuka M: Prognostic value of tumor disappearance rate on computed tomography in advanced-stage lung adenocarcinoma. Clin Lung Cancer; 2007 Mar;8(5):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor disappearance rate on computed tomography in advanced-stage lung adenocarcinoma.
  • BACKGROUND: The proportion of tumor disappearance rate (TDR) on conventional computed tomography (CT) is associated with less aggressive biology, and patients with small peripheral adenocarcinoma accompanied by the TDR component showed better prognosis.
  • These findings led us to the idea that even advanced-stage adenocarcinomas with a higher TDR in the primary lesion on CT might suggest slowly progressing cancer.
  • This study was designed to determine the value of the TDR area in the primary site of advanced-stage lung adenocarcinoma with CT and correlate the CT findings with clinical outcome.
  • PATIENTS AND METHODS: In 103 patients with stage IIIB and IV lung adenocarcinoma, CT appearances and clinical data were reviewed retrospectively.
  • Three methods were used in the evaluation of the TDR area: method I, consolidation on mediastinal windows/mass on lung windows > 75% or not; method II, maximum diameter on mediastinal windows/maximum diameter on lung windows (diameter ratio) > 75% or not; and method III, TDR area on lung windows > 25% or not.
  • RESULTS: In univariate analysis, patients with lung adenocarcinoma with TDR have a more favorable prognosis than those without TDR in all 3 methods (method I, P = 0.001; method II, P = 0.024; method III, P = 0.014; log-rank test).
  • In multivariate analysis, a favorable prognosis in patients with adenocarcinoma with TDR was shown in method I (P = 0.015) and method III (P = 0.006).
  • CONCLUSION: As shown in patients with small peripheral lung adenocarcinoma, those with TDR on CT tended to have a good prognosis in contrast to those without TDR, even in patients with advanced-stage lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / radiography. Lung Neoplasms / mortality. Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562232.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park DY, Sol MY: Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung; 2009 Nov-Dec;187(6):401-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
  • This study was designed to investigate the clinicopathologic significance of CTA expression in non-small-cell lung carcinomas (NSCLCs) and its relationship with immune cells.
  • Immunohistochemical staining to CTAs such as MAGE-A3/6 and NY-ESO-1 was performed using paraffin blocks from 132 cases of NSCLCs, including 75 cases of squamous cell carcinoma (SqCC) and 57 cases of adenocarcinoma (AdC), and the results were evaluated to correlate with tumor-infiltrating DCs and CTLs and clinicopathologic features.
  • In advanced stage III, NY-ESO-1-positive patients showed poorer survival than NY-ESO-1-negative patients.
  • [MeSH-major] Antigens, Neoplasm / immunology. Carcinoma, Non-Small-Cell Lung / immunology. Dendritic Cells / immunology. Lung Neoplasms / immunology. Membrane Proteins / immunology. Neoplasm Proteins / immunology. Tumor Escape
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Humans. Korea. Male. Middle Aged. Neoplasm Staging. Prognosis. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1993 Oct;25(4):338-43 [8164994.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):200-5 [1689143.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):79-88 [16225959.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4296-303 [14555498.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):23-33 [14512184.001]
  • [Cites] Tohoku J Exp Med. 2000 Jun;191(2):113-8 [10946920.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Cancer Lett. 2005 Mar 10;219(2):223-32 [15723723.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):903-8 [9626360.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):351-5 [8322450.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8396-404 [15623618.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1089-98 [16596224.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53 [8692960.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61(6):409-14 [1349780.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Coll Antropol. 2008 Sep;32(3):731-6 [18982744.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7959-63 [11691819.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3478-82 [7627949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] J Exp Med. 1987 Jul 1;166(1):182-94 [2955069.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Nucleic Acids Res. 2004 Aug 17;32(14):4340-50 [15316101.001]
  • [Cites] Annu Rev Immunol. 1991;9:271-96 [1910679.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):325-37 [15772651.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2199-204 [15026363.001]
  • [Cites] Immunol Rev. 2002 Oct;188:33-42 [12445279.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3932-6 [11358808.001]
  • [Cites] Life Sci. 2006 Jul 17;79(8):744-8 [16546222.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Sep;114(1):38-45 [9303329.001]
  • (PMID = 19795170.001).
  • [ISSN] 1432-1750
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / MAGEA3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


21. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H, Ito H: Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication. Lung Cancer; 2009 Aug;65(2):223-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication.
  • We examined the expressions of MCM7 and Ki-67 in lung adenocarcinomas (ACs) with a diameter less than 3cm (pT1), to clarify their pathobiological significance.
  • Kaplan-Meier survival curves showed that patients with higher MCM7 LIs had poorer prognosis in the 100 pT1 ACs as well as in the 73 stage I ACs.
  • Multivariate Cox regression analysis confirmed that the LIs of MCM7, but not the LIs of MCM2 and Ki-67, was an independent prognostic marker in the 73 stage I ACs.
  • These results suggest that MCM7 is an independent prognostic marker, being more reliable than MCM2 or Ki-67 in human pT1 ACs as well as in human stage I ACs.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Cell Cycle Proteins / biosynthesis. DNA-Binding Proteins / biosynthesis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144445.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  •  go-up   go-down


22. Jancarikova D, Pesek M, Benesova L, Topolcan O, Holubec L Jr, Minarik M: Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M. Anticancer Res; 2007 Jul-Aug;27(4A):1879-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.
  • The case of a 32-year-old, non-smoker with non-contributory history patient, who was diagnosed with adenocarcinoma in the left lung T4N0M0 stage IIIB is reported.
  • [MeSH-major] Adenocarcinoma / genetics. Drug Resistance, Neoplasm / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649787.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Kawachi R, Watanabe S, Asamura H: Clinicopathological characteristics of screen-detected lung cancers. J Thorac Oncol; 2009 May;4(5):615-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of screen-detected lung cancers.
  • BACKGROUND: The efficacy of screening for lung cancers remains controversial, and none of the guidelines for lung cancer detection recommend screening for lung cancers.
  • The purpose of the present study was to retrospectively analyze and characterize the clinicopathological features of screen-detected (SCR) lung cancer in comparison with lung cancers detected by other means.
  • PATIENTS: The records of 2281 patients who underwent lung resection for primary lung cancer between 2000 and 2006 were analyzed retrospectively.
  • RESULTS: The percentages of smaller (< or =2 cm) lung cancer (42.6%: SCR, 19.6%: SYM, 40.9%: INC), adenocarcinoma (85.8%: SCR, 58.6%: SYM, 73.1%: INC), and pathologic stage I (73.0%: SCR, 47.0%: SYM, 71.2%: INC) were higher in the SCR group than in the other two groups.
  • The patients with CT-detected lung cancer had a higher incidence of smaller size (< or =2 cm, 76.4%), adenocarcinoma (92.6%), and stage I (clinical: 97.2%, pathologic: 93.1%).
  • CONCLUSIONS: SCR lung cancers were characteristically less advanced, had a smaller diameter, and were more frequently adenocarcinoma histologically.
  • CT-screening may be able to detect early stage lung cancers, and improve the prognosis of lung cancer patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2009 Aug;4(8):1045
  • (PMID = 19318993.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA: FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin; 2005;44(6):249-55; quiz N55-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding.
  • The clinical importance of a FDG PET finding discordant with CT was determined in patients with locally advanced ADE.
  • RESULTS: When read independently from the CT scan FDG PET indicated a clinically relevant change in tumour stage in 9/40 patients (23%) and a non-relevant change in 11/40 patients (28%).
  • In 4/9 patients PET was incorrect (3 false positive due to suspicion of M1-lymph nodes or lung metastases, 1 false negative in disseminated liver metastases).
  • With concomitant reading, PET indicated a clinically relevant change in tumour stage in 6/40 patients (15%) and a non-relevant change in 5/40 patients (13%).
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400385.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Haro-Estarriol M, Casamitjá-Sot MT, Alvarez-Castillo LA, Calderón-López JC, Martínez-Somolinos S, Sebastián-Quetglas F: [Utility of amylase levels in malignant pleural effusions]. Med Clin (Barc); 2007 Sep 22;129(10):372-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Importancia de la determinación de la amilasa pleural en los pacientes con derrame neoplásico.
  • Patients with malignant effusions had higher AL and AR, especially when tumour origin was lung cancer, had positive pleural citology or biopsy and showed an adenocarcinoma.
  • The malignant effusions had higher AL in lung cancer of stage IV.
  • A high AL or AR was related to positive pleural citology or biopsy, a massive pleural effusion and lung cancer with an advanced disease.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915131.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.2.1.- / Amylases
  •  go-up   go-down


26. Thibout Y, Guibert B, Bossard N, Tronc F, Tiffet O, de la Roche E, Mulsant P, Gamondes JP, Baulieux J, Remontet L, Geriniere L, Souquet PJ: Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol; 2009 Dec;4(12):1496-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases.
  • INTRODUCTION: Pneumonectomy (PN) after induction chemotherapy (CT) for non-small cell lung cancer is controversial because high-mortality rates are still reported.
  • Postoperative mortality and morbidity and long-term outcomes were studied.
  • The independent risk factors identified for operative mortality were chronic obstructive pulmonary disease, manual suture of the stump, and pTNM stage higher than IIIA.
  • CONCLUSIONS: Induction CT was not found to compromise short- or long-term outcomes after PN in non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745768.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


27. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, Moriya T, Hayashi S, Handa M, Kondo T, Sasano H: Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. Cancer Res; 2005 Jul 15;65(14):6450-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.
  • A possible involvement of gender-dependent factors has been postulated in development of human non-small-cell lung cancers (NSCLC), but its details remain unclear.
  • Progesterone receptor-positive NSCLC was frequently detected in female and adenocarcinoma, and was inversely associated with tumor-node-metastasis stage and histologic differentiation.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptors, Progesterone / biosynthesis


28. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Out of these 58 patients, adenocarcinoma was most common (n=23, 39.66%).
  • The proportions of advanced-stage patients (stage III B and IV) and moderate to poor-differentiated tumor accounted for 59.26% (16/27) and 77.8% (14/18), respectively in 27 patients with non-small cell lung cancer.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • [MeSH-major] Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Walczyk A, Kowalska A, Sygut J: The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma) - own observations. Endokrynol Pol; 2010 Sep-Oct;61(5):467-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate the clinical course of patients with PDTC, in addition to frequency, clinical stage at the time of diagnosis and the possibility of radical surgical resection, the necessity and kind of complementary treatment, occurrence of distant metastases, and the survival of patients.
  • Distant metastases to the lung and to the brain at diagnosis were observed in 2 patients (14.3%).
  • During follow-up of 3-62 months lung metastases were observed in 4 patients (28.6%), three patients were observed above 5 years as disease-recurrence free (21.5%), but in one patient after 5 years and 2 months distant metastases were diagnosed.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Cell Differentiation. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Iodine Radioisotopes. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049460.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


30. Morgan JL, Khan HN, Lambertz MM: Oesophageal stenting in a district general hospital. Surgeon; 2009 Aug;7(4):203-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most patients with dysphagia present at an advanced stage.
  • Most common causes were advanced adenocarcinoma (34; 60%) and squamous cell carcinoma (16; 28%).
  • Other rarer causes were benign stricture of the oesophagus, lung carcinoma, non-Hodgkin's lymphoma and salivary gland tumour.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736885.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


31. Mireskandari M, Shafaii AF, Kayser G, Kayser K: Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature. Diagn Pathol; 2006;1:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gastric adenocarcinoma is one of the most frequent malignancies worldwide including Iran.
  • This study was designed to immunohistochemically evaluate the CD117 and bcl-2 expression in gastric carcinomas and their potential use as therapeutic targets in the treatment of patients with advanced stage gastric cancer.
  • MATERIALS AND METHODS: Representative paraffin blocks obtained from 38 operated gastric adenocarcinoma patients were retrieved from Afzalipour Hospital pathology department archive, Kerman, Iran.
  • RESULTS: No positive reaction for CD117 was seen in gastric carcinoma tumor cells irrespective to the cell type, grade, and stage, proliferation and apoptosis rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 May 15;103(10):3644-54 [14726395.001]
  • [Cites] Fertil Steril. 1999 Jan;71(1):85-9 [9935121.001]
  • [Cites] Exp Hematol. 2004 Apr;32(4):390-6 [15050750.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):405-9 [15057146.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):527-35 [15141010.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1825-9 [15150607.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):718 [15196872.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):264-76 [15665303.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1228-31 [15754411.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2162-71 [15800309.001]
  • [Cites] Pathol Res Pract. 2005;201(2):71-81 [15901127.001]
  • [Cites] World J Gastroenterol. 2005 Jun 28;11(24):3655-9 [15968715.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Oct;32(11):1540-5 [16315863.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2575-82 [2249198.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):8-13 [2403744.001]
  • [Cites] Cell Growth Differ. 1995 Jun;6(6):769-79 [7545433.001]
  • [Cites] Cell Growth Differ. 1995 Sep;6(9):1111-8 [8519688.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3397-402 [9042197.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3192-203 [10880433.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1267-73 [10942367.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):16-26 [11197247.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):90-4 [11388751.001]
  • [Cites] Dig Dis Sci. 2002 Jan;47(1):107-13 [11837709.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):183-5 [11863213.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):188-93 [11865845.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):1-22 [12072198.001]
  • [Cites] Exp Hematol. 2002 Jul;30(7):767-73 [12135675.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4879-83 [12208734.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):60-5 [12532420.001]
  • [Cites] Exp Hematol. 2003 Feb;31(2):109-17 [12591275.001]
  • [Cites] Gene Expr Patterns. 2003 Mar;3(1):53-8 [12609603.001]
  • [Cites] Lung Cancer. 2003 May;40(2):173-80 [12711118.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2329-33 [12894511.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4305-8 [14666642.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Dec;3(6):757-66 [14686698.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):305-13 [14695343.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):46-55 [14709738.001]
  • [Cites] World J Gastroenterol. 2005 Oct 7;11(37):5899-901 [16270406.001]
  • [Cites] J Cell Physiol. 1997 Jul;172(1):1-11 [9207920.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):327-33 [9440029.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):751-61 [14760098.001]
  • (PMID = 16759362.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1475889
  •  go-up   go-down


32. Germain F, Wai ES, Berthelet E, Truong PT, Lesperance M: Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy. Am J Clin Oncol; 2008 Dec;31(6):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis is an early manifestation of distant failure in stage III nonsmall cell lung cancer patients treated with radical chemoradiation therapy.
  • OBJECTIVES: To evaluate the patterns of distant relapse, focusing on brain metastasis, in patients with stage III nonsmall cell lung cancer (NSCLC) treated with radical chemoradiation therapy (CRT).
  • METHODS: The British Columbia Cancer Agency provincial database identified 2268 patients presenting with stage III NSCLC between January 1, 1990 and December 31, 2000.
  • Variables analyzed included gender, age, Eastern Cooperative Oncology Group performance status, stage, histology, sites of metastasis, and survival.
  • There were 74 stage IIIA and 46 stage IIIB cases.
  • Histologic subtypes were squamous cell carcinoma (n = 29), adenocarcinoma (n = 53), and other non-squamous histologies (n = 38).
  • CONCLUSIONS: Stage III NSCLC patients treated with CRT have high risks of brain metastasis which persist during the first 10 months after diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis


33. Nawrocki S, Krzakowski M, Wasilewska-Tesluk E, Kowalski D, Rucinska M, Dziadziuszko R, Sowa A: Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study. J Thorac Oncol; 2010 Aug;5(8):1255-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.
  • INTRODUCTION: The optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (NSCLC) not eligible for surgery and definitive chemoradiotherapy is unknown.
  • METHODS: Patients with stage IIIA to IIIB NSCLC with tumor >8 cm and/or forced expiratory volume < or =40%, performance status 0 to 2, and tumor-related chest symptoms were randomly assigned to arm A: radiotherapy alone (30 Gy/10 fractions) or arm B: chemoradiotherapy (two cycles of cisplatin and vinorelbine followed by radiotherapy together with third cycle).
  • CONCLUSIONS: Upfront chemotherapy combined with palliative radiotherapy (30 Gy) is a promising treatment option in the subpopulation of patients with stage IIIA to IIIB NSCLC not amenable for definitive chemoradiotherapy and deserves further investigation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592630.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


34. Iwasaki A, Shirakusa T, Maekawa T, Enatsu S, Maekawa S: Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection. Eur J Cardiothorac Surg; 2005 Jan;27(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection.
  • To date, there has been no report of SIRS after surgery in patients with lung cancer.
  • Among these 720 patients, a curative approach was attempted in 144 with advanced stage (T3, 100; T4, 44) cancer.
  • Duration of SIRS after lung surgery was associated with high levels in WBC and low %FEV1.
  • The 1-year survival was as follows; G1, 75.4%; G2, 47.9%; G3, 38.1%.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Lung Neoplasms / complications. Systemic Inflammatory Response Syndrome / complications
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Staging. Postoperative Care / methods. Postoperative Complications / etiology. Postoperative Complications / mortality. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621464.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Dusenbery KE, Potish RA, Gold DG, Boente MP: Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecol Oncol; 2005 Mar;96(3):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The present review analyzes long-term survival, recurrence sites, and toxicity in women with peritoneal spread of endometrial treated with abdominal radiotherapy, in order to provide therapeutic options as a function of disease spread and histology.
  • RESULTS: FIGO stage distribution was 54 stage IIIA, 2 stage IIIB, 11 stage IIIC, and 19 stage IVB.
  • Recurrence rates were 16% for stage IIIA with one peritoneal site, 48% for stage IIIA with multiple peritoneal sites or stage IIIB or stage IIIC, and 72% for stage IVB.
  • With univariate analysis, statistical significance was found for stage, gross peritoneal disease, nodal metastases, histology, concurrent chemotherapy, isolated adnexal spread, grade, angiolymphatic invasion, myometrial invasion, and age.
  • Multivariate analysis found only stage, histology, and age to be significant.
  • CONCLUSIONS: Abdominal radiotherapy confers an excellent prognosis for women with stage IIIA cancers with one site of peritoneal involvement.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiotherapy. Adenocarcinoma, Papillary / secondary. Adult. Aged. Aged, 80 and over. Cohort Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Cystadenocarcinoma, Serous / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy / adverse effects. Radiotherapy / methods. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721405.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Popescu I: [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention]. Pneumologia; 2008 Oct-Dec;57(4):201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Leziunile bronşice pre-neoplazice: posibilităţi de diagnostic şi chemo-prevenţie.
  • Pre-neoplastic bronchial lesions are the first stage in the evolution towards invasive cancers.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186682.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0 / Tumor Suppressor Protein p53; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 48
  •  go-up   go-down


37. Stinchcombe TE, Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc; 2009 Apr 15;6(2):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatments for advanced stage non-small cell lung cancer.
  • Lung cancer remains the leading cause of cancer mortality in the United States, and the majority of patients will have non-small cell lung cancer (NSCLC) and will present with locally advanced or metastatic disease.
  • In the United States, the most common histology is adenocarcinoma, followed by squamous cell, large cell, and not otherwise specified.
  • Despite the improvements in care and number of therapeutic agents available, the survival for patients with advanced-stage NSCLC remains modest; novel approaches are required and participation in clinical trials should be encouraged.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


38. Kaur A, Falleiro JJ, Ghosh AK, Mani NS: Pulmonary carcinosarcoma masquerading as a cryptic disseminated malignancy. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):517-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At autopsy, it was a stage IV lung malignancy and histopathology revealed a carcinosarcoma comprising an adenocarcinoma and an osteosarcoma with metastasis to the heart, lymph nodes, and both adrenals.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805960.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


39. Kim HT, Han JY, Lee DH, Chun JH, Lee HG, Lee JJ, Kim HY, Lee SY, Lee JS: A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer; 2006 Aug 15;107(4):799-805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
  • BACKGROUND: Irinotecan (1) and cisplatin (P) are active chemotherapy agents with clinical synergy in non-small-cell lung cancer (NSCLC).
  • Twenty-five patients had adenocarcinoma and 6 had squamous-cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826586.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


40. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K: Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer; 2006 Nov 15;107(10):2468-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma.
  • BACKGROUND: [(18)F]Fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been frequently used for diagnosis and staging of lung cancer.
  • The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).
  • METHODS: Disease-free survival of 98 patients with pathologic Stage I lung adenocarcinoma who were treated by curative resection was examined in relation to sex, age, histologic grade of differentiation, surgical procedure, tumor stage, and FDG uptake measured as the maximum standardized uptake value (SUV).
  • RESULTS: Sixty-three patients were had Stage IA disease and 35 patients had Stage IB disease.
  • Six patients each with Stage IA and Stage IB disease developed disease recurrence after a mean postsurgical follow-up period of 31 months.
  • Ten (20%) of the 51 patients with moderately or poorly differentiated adenocarcinoma developed disease recurrence, compared with 2 (4%) of the 47 patients with well-differentiated adenocarcinoma (P = .056).
  • CONCLUSIONS: FDG uptake appears to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036361.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Wu YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, Zhou Q, Xu CR, Wang Z: [Gefitinib target treatment in non-small cell lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb;30(2):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib target treatment in non-small cell lung cancer].
  • OBJECTIVE: To evaluate the efficacy, target population and influencing factors of Gefitinib in patients with non-small-cell lung cancer (NSCLC) pretreated with platinum.
  • Adenocarcinoma was the only predictor for therapeutic effect in the Cox model (P = 0.004).
  • CONCLUSION: Gefitinib is the drug of choice for patients with heavily pretreated stage III(B) and IV adenocarcinoma of NSCLC with safe and accepted toxicity profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445469.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


42. Ishihara T, Takeuchi T, Nishimori I, Adachi Y, Minakuchi T, Fujita J, Sonobe H, Ohtsuki Y, Onishi S: Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma. Virchows Arch; 2006 Jun;448(6):830-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
  • Carbonic anhydrase-related protein VIII (CA-RP VIII) is believed to be an oncofetal antigen and is overexpressed in colorectal and non-small cell lung cancer.
  • However, the pathobiological properties of CA-RP VIII in lung cancer remain unclear.
  • In the present study, we examined ultrastructural changes caused by exogenous CA-RP VIII expression in a well-differentiated lung adenocarcinoma cell line, PC-9.
  • We subsequently examined CA-RP VIII expression in atypical adenomatous hyperplasia and early-stage lung adenocarcinoma (Stage Ia).
  • Significant expression of CA-RP VIII was observed in invasive lung adenocarcinoma but not in noninvasive adenocarcinoma.
  • Interestingly, CA-RP VIII was strongly expressed in signet-ring cell cancer and invasive mucinous adenocarcinoma components.
  • The present findings suggest that CA-RP VIII expression in lung adenocarcinoma is related to cancer cell invasion.
  • [MeSH-major] Carbonic Anhydrases / genetics. Carcinoma, Non-Small-Cell Lung / ultrastructure. Gene Expression Regulation, Neoplastic. Lung Neoplasms / ultrastructure. Nerve Tissue Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):663-72 [11159203.001]
  • [Cites] Neuroscience. 2002;112(1):93-9 [12044474.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5537-44 [12944900.001]
  • [Cites] Virchows Arch. 2003 Jan;442(1):66-70 [12536316.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):189-93 [9630625.001]
  • [Cites] J Pathol. 2003 Sep;201(1):37-45 [12950015.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17213-20 [11279065.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1489-97 [10737605.001]
  • [Cites] J Pathol. 1988 Sep;156(1):23-7 [3057151.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):868-74 [15223955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4874-9 [10220386.001]
  • [Cites] Ann Rheum Dis. 2003 Mar;62(3):196-203 [12594102.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):273-80 [15140539.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):806-13 [8077365.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):435-41 [12611586.001]
  • [Cites] J Biol Chem. 1990 Apr 5;265(10):5573-8 [2318825.001]
  • [Cites] FEBS Lett. 1990 Oct 1;271(1-2):137-40 [2121526.001]
  • (PMID = 16609906.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA8 protein, human; 0 / Car8 protein, mouse; 0 / Mucins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


43. Zhu ZH, Yang H, Fu JH, Hu Y, Ma Y, Wu QL, Rong TH, Wang DF: [Expression and prognostic value of survivin protein in early-stage non-small cell lung cancer]. Ai Zheng; 2007 Nov;26(11):1268-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and prognostic value of survivin protein in early-stage non-small cell lung cancer].
  • This study was to investigate the expression and prognostic value of Survivin in early-stage non-small cell lung cancer (NSCLC).
  • Among the 39 patients with small lung adenocarcinoma (tumor diameter of <3 cm), the difference in survival between Survivin-positive and Survivin-negative groups was not significant (P>0.05).
  • CONCLUSION: The prognostic value of Survivin in early-stage NSCLC is unclear.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Microtubule-Associated Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991331.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


44. Takimoto T, Hirashima T, Kobayashi M, Nitta T, Sasada S, Nakamura Y, Matsui K, Kawahara K, Kawase I: Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution. Gan To Kagaku Ryoho; 2005 Nov;32(12):1985-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
  • Gefitinib has a modest activity in previously treated patients with advanced non-small cell lung cancer (NSCLC).
  • The histological types were adenocarcinoma in all patients.
  • Clinical stage was IIB in one patient, IIIB in four, and IV in seven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


45. Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, Li N, Zhou J, He E, Skog S: Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev; 2010 Jul;19(4):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
  • For this purpose we used sera from patients with oesophageal (n=101) and cardial (n=39) carcinomas and nonsmall-cell lung carcinoma (NSCLC) (n=157).
  • The mean STK1 value of oesophageal carcinoma patients correlated with T-values (P=0.021) and with stage (P<0.005), but not with grade.
  • No data on stage and T-values were available for these patients, due to advanced disease.
  • The mean STK1 value of NSCLC patients with squamous cell carcinoma was significantly higher as compared with adenocarcinoma type (P=0.024).
  • The mean STK1 value of the NSCLC patients correlated with clinical grade (P=0.006), T-values (P=0.001), stage (P=0.035) and to size of the tumour (P=0.030).
  • There was a tendency that stage I-II NSCLC patients with an STK1 level above 2 pmol/l showed a higher frequency of recurrence/death than patients below 1 pmol/l.
  • Our results show that STK1 is a useful marker for prognosis in patients with oesophageal, cardial and lung carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Esophageal Neoplasms / blood. Heart Neoplasms / blood. Lung Neoplasms / blood. Thymidine Kinase / blood

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479645.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


46. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • A survival analysis showed no significant prognostic difference between the patient age, gender, pathological stage, synchronous/metachronous classification, CEA, and site of metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


47. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA: Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol; 2009 May;131(5):694-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
  • Micropapillary lung adenocarcinoma (MPA) has been reported as an aggressive variant of adenocarcinoma, frequently manifesting at high stage with a poor prognosis.
  • We conclude that K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Genes, erbB-1 / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 May;131(5):615-7 [19369618.001]
  • (PMID = 19369630.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Mucins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


48. Chen XL, Zhang WG, Chen XY, Sun ZM, Liu SH: [Correlations of S100A4 protein expression to invasion and metastasis of non-small cell lung cancer]. Ai Zheng; 2006 Sep;25(9):1134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of S100A4 protein expression to invasion and metastasis of non-small cell lung cancer].
  • This study was to determine the expression of S100A4 in human non-small cell lung cancer (NSCLC), and to investigate its correlations to invasion and metastasis of NSCLC.
  • METHODS: The expression of S100A4 in 41 specimens of NSCLC and 6 specimens of normal lung tissues was detected by SP immunohistochemistry.
  • RESULTS: The positive rate of S100A4 was significantly higher in NSCLC than in normal lung tissues (70.7% vs. 16.7%, P<0.05), and was significantly higher in adenocarcinoma than in squamous cell carcinoma (90.0% vs. 52.4%, P<0.01).
  • The positive rate of S100A4 was significantly higher in stage III-IV than in stage II and stage I NSCLC (100.0% vs. 66.7% and 30.0%, P<0.01), while there was no obvious difference between the latter 2 groups (P>0.05).
  • CONCLUSION: S100A4 expression is up-regulated in NSCLC, and closely related to lymphatic metastasis, TNM stage and tumor size, which suggest an important role of S100A4 in the invasion and metastasis of NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. S100 Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging


49. Franceschini J, Santos AA, El Mouallem I, Jamnik S, Uehara C, Fernandes AL, Santoro IL: [Assessment of the quality of life of patients with lung cancer using the Medical Outcomes Study 36-item Short-Form Health Survey]. J Bras Pneumol; 2008 Jun;34(6):387-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of the quality of life of patients with lung cancer using the Medical Outcomes Study 36-item Short-Form Health Survey].
  • [Transliterated title] Avaliação da qualidade de vida em pacientes com câncer de pulmão através da aplicação do questionário Medical Outcomes Study 36-item Short-Form Health Survey.
  • OBJECTIVE: To assess the quality of life of patients with lung cancer and to compare it with that of individuals without cancer.
  • METHODS: The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) was administered to 57 patients diagnosed with lung cancer, treated at the Lung Cancer Outpatient Clinic of the Hospital São Paulo, and to a control group of 57 individuals recruited from the Extra Penha workout group.
  • The second model was adjusted for each SF-36 domain in order to identify increases in the proportions of patients in stage IIIB or IV.
  • RESULTS: The lung cancer group and the control group presented the following mean scores, respectively, for the SF-36 domains: role limitations due to physical health problems, 29.39 +/- 36.94 and 82.89 +/- 28.80; role limitations due to emotional problems, 42.78 +/- 44.78 and 86.55 +/- 28.77; physical function, 56.49 +/- 28.39 and 89.00 +/- 13.80; vitality, 61.61 +/- 23.82 and 79.12 +/- 17.68; bodily pain, 62.72 +/- 28.72 and 81.54 +/- 19.07; general health, 62.51 +/- 25.57 and 84.47 +/- 13.47; emotional well-being, 68.28 +/- 23.46 and 82.63 +/- 17.44; and social functioning, 72.87 +/- 29.20 and 91.67 +/- 17.44.
  • CONCLUSIONS: The patients with lung cancer had a poorer quality of life, especially regarding physical aspects, than did the control subjects.
  • [MeSH-major] Adenocarcinoma / psychology. Carcinoma, Squamous Cell / psychology. Lung Neoplasms / psychology. Quality of Life / psychology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622506.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


50. Shi Y, Chen L, Li J, Lü YL, Jiao SC: [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug;32(4):375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
  • OBJECTIVE: To determine the predictive value of excision repair cross complementation group 1 (ERCC1),ribonucleotide reductase subunit M1 (RRM1), and β-tubulin 3 expressions in postoperative patients with stage 1- 3 non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy.
  • Univariate survival analysis showed that sex, clinical stage,and adenocarcinoma or not were related to DFS, while age, smoke history, chemotherapy regimens, and expression levels of ERCC1, RRM1, and β-tubulin 3 has no prognostic significance in these surgically resected NSCLC patients who were receiving adjuvant chemotherapy.
  • Male (P=0.036), earlier clinical stage (P=0.001), and non-adenocarcinoma (P=0.004) predicted better DFS.
  • COX proportional regression analysis showed that adenocarcinoma or not and clinical stage were independent risk factors of DFS in this population.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Lung Neoplasms / drug therapy. Tubulin / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20868593.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RRM1 protein, human; 0 / Tubulin; 0 / Tumor Suppressor Proteins; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


51. Watanabe K, Ishida T, Fukuhara A, Sekine S, Uekita K, Sugawara A, Tachihara M, Kanazawa K, Saito J, Tanino Y, Munakata M: [A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1595-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 70-year-old woman with cough was diagnosed with pulmonary adenocarcinoma by bronchoscopic transbronchial biopsy.
  • She was diagnosed cT2N0M0, stage IB clinically, and the tumor was surgically resected.
  • Postoperative pathology was confirmed to be pleomorphic carcinoma of pT2N2M0, stage III A.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799919.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


52. Wang X, Zheng L, Zhang SY, Xie ZM, Yu H, Su XD, Wang JY, Huang ZF, Yang MT, Rong TH: [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].
  • OBJECTIVE: To discuss the strategy of mediastinoscopy for the evaluation of mediastinal lymph node status (metastasis or not) of non-small cell lung cancer (NSCLC) prior to surgery.
  • In clinical stage I (cT1-2N0M0) NSCLC the positive rate of mediastinoscopy was 11.3% (7/62), N2 accounting for 6.5% (4/62) and N3 4.8% (3/62), respectively; and the prevalence of mediastinal lymph node metastasis was 19.4% (12/62), N2 ccounting for 14.6% (9/62) and N3 4.8% (3/62), respectively.
  • In the whole group both univariate and multivariate analysis showed that adenocarcinoma or mediastinal lymph nodes > or =1 cm in the shortest axis on CT scan was an independent risk factor to predict mediastinal lymph node metastasis.
  • In NSCLC with negative mediastinal or hilar lymph nodes on CT scan both univariate and multivariate analysis showed that adenocarcinoma was a predictor of mediastinal lymph node metastasis.
  • Adenocarcinoma also indicates mandatory mediastinoscopy even with negative mediastinal or hilar lymph nodes on CT scan.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mediastinoscopy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Adult. Aged. Carcinoembryonic Antigen / blood. Female. Humans. Logistic Models. Male. Mediastinum. Middle Aged. Neoplasm Staging. Preoperative Period. Risk Factors. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


53. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol; 2006 Apr 20;24(12):1807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Advanced bronchioloalveolar carcinoma (BAC) is a distinct subtype of non-small-cell lung cancer (NSCLC) for which there is currently no optimal therapy.
  • Toxicity consisted mainly of rash and diarrhea, but 2% of patients died of presumed interstitial lung disease.
  • CONCLUSION: Gefitinib is an active agent in advanced stage BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA74547; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


54. Ayabe T, Matsuzaki Y, Shimizu T, Hara M, Tomita M, Onitsuka T: [pN0 stage IA lung cancer downstaged from pN2 IIIA by induction therapy; report of a case]. Kyobu Geka; 2006 Sep;59(10):955-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [pN0 stage IA lung cancer downstaged from pN2 IIIA by induction therapy; report of a case].
  • A 75-year-old male of adenocarcinoma in non-small cell lung cancer (NSCLC) was diagnosed to be p-staged IIIA by a preoperative mediastinoscopy.
  • The postoperative stage has been down to be pN0 IA from pN2 IIIA.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / surgery. Lymph Node Excision. Mediastinoscopy. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986695.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Zhang XY, Dong QG, Huang JS, Huang AM, Shi CL, Jin B, Sha HF, Feng JX, Geng Q, Zhou J, Xu HL, Han BH: The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J Surg Oncol; 2010 Dec 1;102(7):856-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma.
  • INTRODUCTION: The purpose of the present study was to detect the presence of BASC-like stem cell-related indicators, such as clara cell secretory protein (CCSP), Octamer-4 (OCT4) and Bmi-1, and evaluate their implications in the prognosis of patients with lung adenocarcinoma.
  • METHODS: Specimens of 134 cases of lung adenocarcinoma were collected after radical surgery from January 1999 to June 2004.
  • Bmi-1 was significantly higher in patients at stage III compared to patients at stages I and II.
  • The pattern of survival curves showed that Bmi-1 was a significant prognostic factor of poor overall survival in lung adenocarcinoma patients (P = 0.0000), and the patients with OCT4(+) expression showed a greater increase in mortality than OCT4(-) patients (P = 0.0103).
  • CONCLUSIONS: OCT4 and Bmi-1 may be good biomarkers to predict the prognosis of patients with completely resected lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / metabolism. Octamer Transcription Factor-3 / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism. Uteroglobin / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20818602.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Nuclear Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / SCGB1A1 protein, human; 9060-09-7 / Uteroglobin; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


56. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J, Shih NY: Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res; 2006 Oct 1;12(19):5746-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes.
  • PURPOSE: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer.
  • EXPERIMENTAL DESIGN: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies.
  • Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables.
  • RESULTS: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells.
  • The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes.
  • [MeSH-major] Autoantigens / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Phosphopyruvate Hydratase / metabolism. Pleural Effusion, Malignant / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Aged. Carcinoma, Large Cell / enzymology. Carcinoma, Squamous Cell / enzymology. Female. Humans. Male. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020980.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


57. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL: KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res; 2007 Jun 01;13(11):3229-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer.
  • PURPOSE: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer.
  • Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma.
  • RESULTS: Squamous cell carcinoma had the highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002).
  • KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex.
  • In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95% confidence interval, 1.09-1.94)].
  • Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar.
  • CONCLUSIONS: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Kinesin / genetics. Kinesin / physiology. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Oncogene Proteins / genetics. Oncogene Proteins / physiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545527.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118830; United States / NCI NIH HHS / CA / R01 CA118830-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / RNA, Small Interfering; EC 3.6.1.- / KIF14 protein, human; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


58. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y: Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg; 2006 Aug;5(4):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the histological subtype in completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC), which includes several different histological subtypes, is usually treated by the same strategy.
  • The overall 5- and 10-year survivals of the patients with adenocarcinoma (AD), squamous cell carcinoma (SQ), large cell carcinoma (LA), and adenosquamous cell carcinoma (AS) were 54.2 and 40.2%, 51.6 and 30.3%, 40.9 and 18.7%, and 35.1 and 30.1%, respectively.
  • The AD patients had a significantly better survival than the non-AD patients in Stage I (P=0.0004), whereas the SQ patients had a better survival than the non-SQ patients in Stage II (P=0.018).
  • A multivariate survival analysis indicated the AD patients to have a significantly better survival than the SQ patients in Stage IA (P=0.04), while the SQ patients had a better survival than the AD patients in Stage II (P=0.03).
  • These above observations suggest that the prognosis after complete resection is different between adenocarcinoma and squamous cell carcinoma in Stage IA and II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670594.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC: A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res; 2007 Jun 15;67(12):5889-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.
  • The development of new modes of diagnosis and targeted therapy for lung cancer is dependent on the identification of unique cell surface features on cancer cells and isolation of reagents that bind with high affinity and specificity to these biomarkers.
  • We recently isolated a 20-mer peptide which binds to the lung adenocarcinoma cell line, H2009, from a phage-displayed peptide library.
  • We show here that the cellular receptor for this peptide, TP H2009.1, is the uniquely expressed integrin, alphavbeta6, and the peptide binding to lung cancer cell lines correlates to integrin expression.
  • Expression of alphavbeta6 was assessed on 311 human lung cancer samples.
  • The expression of this integrin is widespread in early-stage nonsmall cell lung carcinoma (NSCLC).
  • Preferential expression is observed in the tumors compared with the surrounding normal lung tissue.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575158.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HV / N01-HV-28185; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA106646; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1 R01 CA 106646-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Peptide Library; 0 / Peptides; 0 / integrin alphavbeta6
  •  go-up   go-down


60. Monego G, Lauriola L, Ramella S, D'Angelillo RM, Lanza P, Granone P, Ranelletti FO: Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 expression in human lung adenocarcinoma. Chest; 2010 Apr;137(4):898-908
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 expression in human lung adenocarcinoma.
  • In non-small cell lung carcinoma the clinical relevance of the expression of PTH1R remains to be investigated.
  • METHODS: Fifty-four lung adenocarcinomas of mixed histologic type from patients with stage I and II cancer were assayed by quantitative immunohistochemistry for the expression of PTHrP and PTH1R.
  • CONCLUSION: The paracrine/autocrine signaling through PTHrP/PTH1R could be important in early-stage lung adenocarcinoma progression.
  • [MeSH-major] Adenocarcinoma / metabolism. Lung Neoplasms / metabolism. Parathyroid Hormone-Related Protein / metabolism. Receptor, Parathyroid Hormone, Type 1 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952062.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / Receptor, Parathyroid Hormone, Type 1
  •  go-up   go-down


61. Hanazawa K, Higashi N, Kawachi Y, Suzuki F, Ishi K, Fujime M: Small cell carcinoma of the prostate with hypercalcemia. Int J Urol; 2005 Jan;12(1):108-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed as having stage T3bN1M0 adenocarcinoma of the prostate.
  • The autopsy revealed small cell carcinoma of the prostate and multiple metastasis of the lung, liver, pancreas, lymph nodes and spine.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661065.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


62. Schallier D, Bral S, Ilsen B, Neyns B, Fontaine C, Decoster L, De Mey J, Meysman M, De Grève J: Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol; 2009 Jun;4(6):728-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
  • INTRODUCTION: We report the long term and overall results of a triplet induction chemotherapy regimen followed by standard radiotherapy in patients with locally advanced inoperable stage III non-small cell lung cancer.
  • RESULTS: Sixty-four patients (25 stage IIIA and 39 stage IIIB) received a total of 179 cycles of chemotherapy.
  • Median time to progression was 10.9 month and median overall survival was 17.2 month, with a significant difference between stage IIIA and stage IIIB patients (23.4 versus 10.5 month; p = 0.011).
  • The strongest predictor for a favorable long-term outcome was a metabolic complete response after chemotherapy.
  • CONCLUSION: Induction chemotherapy with the paclitaxel, carboplatin, and gemcitabine regimen preceding radiotherapy in patients with locally advanced inoperable stage III non-small cell lung cancer was feasible and active.
  • Long-term survival results of this sequential chemoradiotherapy regimen appear similar to those of concurrent treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose Fractionation. Feasibility Studies. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404217.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


63. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis.
  • Approximately one third of NSCLC patients present with early-stage disease in which potentially curative resection and multi-modality therapy.
  • Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic efficacy of adjuvant chemotherapy, following complete surgical resection of early stage NSCLC, has not been fully established.
  • Several prospective randomized trials for patients with early stage NSCLC (stages I-IIIA) have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 meta-analysis performed by the NSCLC Collaborative Group.
  • Studies from Japan have reported that adjuvant therapy with uracil-tegaful (UFT) afforded an improvement of 4% in the 5-year survival rate and a relative risk reduction of 26% in mortality at 5 years among patients with T1-2N0 (stage I) disease.
  • In particular, the Japan Lung Cancer Research Group has demonstrated an improvement in the 5-year survival rate of 11%, favoring chemotherapy with UFT in the subset of patients with T2N0 (stage IB) disease.
  • The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled analysis of five randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC.
  • This benefit depended on stage, being greatest in patients with stage II or IIIA disease.
  • This analysis has suggested that platinum-based adjuvant chemotherapy may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505412.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 18
  •  go-up   go-down


64. Duan Y, Bai LQ: [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jun 16;89(23):1630-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma].
  • OBJECTIVE: Observe the effect of operation plus post-operative chemotherapy for long-term results of stage I lung adenocarcinoma.
  • METHODS: From January 1994 to January 2005, 427 patients with stage I lung adenocarcinoma underwent surgical resection therapy.
  • The comparison of long-term survival rates was made between post-chemotherapy and surgical resection alone.
  • RESULTS: The analyses disclosed that the stage I a 1, 3, 5 and 10-year survival rate of post-chemotherapy was 100.00%, 92.34%, 86.17% and 74.82%, respectively, while in surgical resection alone was 96.63%, 88.11%, 79.52% and 65.85%, respectively.
  • The stage I b 1, 3, 5 and 10-year survival rate of post-chemotherapy was 96.84%, 77.99%, 69.56% and 64.36%, respectively, while in surgical resection alone was 85.65%, 67.11%, 59.56% and 53.06%, respectively.
  • There was statistically significant difference between 1 year survival rate of stage I a patients with post-chemotherapy and those with surgical resection alone (P < 0.05); 1 year survival rate of stage I b patients with post-chemotherapy and those with surgical resection alone (P < 0.01).
  • CONCLUSION: The operation plus post-operative chemotherapy is better than surgical resection alone in stage I a and I b.
  • Surgical plus post-operative chemotherapy mode is indispensable for better prognosis of stage I a and I b lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957512.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, Singer RH, Pikarsky E, Yisraeli JK: A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol; 2008 Aug;215(4):445-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients, VICKZ expression varies with tumour type, with over 60% of colon, lung, and ovarian tumours showing strong expression.
  • Indeed, in stage II CRC, the level of VICKZ expression in the primary lesion correlates with the degree of lymph node metastasis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] J Cell Sci. 1995 Aug;108 ( Pt 8):2781-90 [7593319.001]
  • [Cites] J Cell Biol. 1994 Sep;126(5):1221-9 [8063859.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1263-70 [9087442.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Biol Cell. 1997 May;89(2):113-22 [9351191.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1593-8 [9620847.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1202-5 [10096548.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48716-24 [15355996.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Biol Cell. 2005 Jan;97(1):87-96 [15601260.001]
  • [Cites] Biol Cell. 2005 Jan;97(1):97-110 [15601261.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1976-8 [15731405.001]
  • [Cites] Oncologist. 2005 May;10(5):332-4 [15851791.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18517-24 [15753088.001]
  • [Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2425-33 [15923655.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4545-52 [16002846.001]
  • [Cites] Reproduction. 2005 Aug;130(2):203-12 [16049158.001]
  • [Cites] Nature. 2005 Nov 24;438(7067):512-5 [16306994.001]
  • [Cites] EMBO J. 2006 Apr 5;25(7):1456-68 [16541107.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2581-91 [16597702.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):898-901 [16778892.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Nat Neurosci. 2006 Oct;9(10):1247-56 [16980963.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):527-34 [17101699.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):434-42 [17255263.001]
  • [Cites] Haematologica. 2007 Feb;92(2):176-83 [17296566.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):798-811 [17289661.001]
  • [Cites] RNA. 2007 Sep;13(9):1558-69 [17652133.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):54-9 [12532419.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1519-28 [10734311.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7045-50 [11416185.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6544-50 [11641779.001]
  • [Cites] Gene. 2002 Apr 3;287(1-2):49-54 [11992722.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):77-87 [12507992.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):119-24 [12517787.001]
  • [Cites] Curr Biol. 2003 Feb 4;13(3):199-207 [12573215.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Development. 2003 Dec;130(23):5649-61 [14522877.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):209-14 [14729626.001]
  • [Cites] Science. 2004 Apr 30;304(5671):743-6 [15118165.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1890-909 [15203104.001]
  • [Cites] Cell. 1986 May 9;45(3):407-15 [3698103.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):458-63 [2036925.001]
  • [Cites] J Cell Biol. 1994 Sep;126(5):1211-9 [8063858.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2158-65 [9121465.001]
  • (PMID = 18535985.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR041480-13; United States / NIGMS NIH HHS / GM / R01 GM084364-17; United States / NIAMS NIH HHS / AR / R01 AR041480-11; United States / NIAMS NIH HHS / AR / AR041480-06; United States / NIAMS NIH HHS / AR / AR041480-11; United States / NIGMS NIH HHS / GM / R01 GM084364-15A1; United States / NIAMS NIH HHS / AR / R01 AR041480-10A2; United States / NIAMS NIH HHS / AR / AR041480-10A2; United States / NIAMS NIH HHS / AR / AR041480-09; United States / NIAMS NIH HHS / AR / R01 AR041480; United States / NIGMS NIH HHS / GM / R01 GM084364-18; United States / NIAMS NIH HHS / AR / R01 AR041480-09; United States / NIAMS NIH HHS / AR / AR041480-08; United States / NIAMS NIH HHS / AR / R01 AR041480-06; United States / NIAMS NIH HHS / AR / R01 AR041480-14; United States / NIGMS NIH HHS / GM / R01 GM084364-16; United States / NIAMS NIH HHS / AR / R01 AR041480-08; United States / NIAMS NIH HHS / AR / R01 AR041480-11S1; United States / NIAMS NIH HHS / AR / R01 AR041480-12; United States / NIGMS NIH HHS / GM / R01 GM084364
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / ZBP1 protein, human
  • [Other-IDs] NLM/ NIHMS314194; NLM/ PMC3148580
  •  go-up   go-down


66. Sheikh HA, Sasatomi E, Finkelstein S, Yousem SA: Comparative mutational analysis of pulmonary scar epithelium, bronchioloalveolar carcinomas, and invasive well-differentiated pulmonary adenocarcinomas: a molecular approach to diagnostically challenging cases. Am J Surg Pathol; 2005 Oct;29(10):1267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Discrimination of invasive well-differentiated adenocarcinoma (IAD) from reactive bronchioloalveolar epithelium entrapped in pulmonary scars (PSE) may be difficult on routine histology, especially on small biopsies.
  • In this study, we compared cumulative loss of heterozygosity (LOH) of tumor suppressor genes in PSEs (N = 12), bronchioloalveolar carcinomas (BACs, N = 15) and stage 1 IADs (N = 7).
  • These molecular differences may serve as an adjunct to histology in challenging glandular lesions of the lung.
  • [MeSH-major] Cicatrix / genetics. DNA, Neoplasm / analysis. Lung Diseases / genetics. Lung Neoplasms / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. DNA Mutational Analysis. Diagnosis, Differential. Genes, Tumor Suppressor / physiology. Humans. Loss of Heterozygosity. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Scars.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160467.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


67. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F: Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology; 2009 Apr;54(5):590-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.
  • AIMS: To evaluate whether there is a correlation between the subcellular localization of maspin and the histological, molecular and biological features of pulmonary adenocarcinoma, particularly addressing the hypothesis that the tumour inhibitor properties of maspin may be linked to a nuclear, compared with a combined nuclear and cytoplasmic expression pattern.
  • METHODS AND RESULTS: The subcellular expression of maspin was determined in 80 resected pulmonary adenocarcinomas (Stage I, 46; Stage II, 10; Stage III, 20; Stage IV, 4) and correlated with histological grade, proliferative rate, p53 expression, vascular endothelial growth factor (VEGF)-A levels, and prognosis (mean follow-up of 41.5 months).
  • Cox multivariate analysis revealed in stage I adenocarcinomas (N) maspin as the only predictor of improved survival.
  • CONCLUSIONS: (N) maspin selects lung adenocarcinomas with distinct molecular and clinical features, supporting the hypothesis that its tumour inhibitor properties may be linked to its nuclear localization.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9 [11206229.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3691-8 [17530022.001]
  • [Cites] Clin Biochem. 2001 Jun;34(4):303-7 [11440731.001]
  • [Cites] J Pathol. 2001 Oct;195(3):321-6 [11673829.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):54-60 [11801540.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):452-5 [12115529.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):59-69 [12531692.001]
  • [Cites] J Pathol. 2003 Apr;199(4):432-5 [12635133.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):863-70 [12644823.001]
  • [Cites] Histopathology. 2003 Jun;42(6):541-5 [12786889.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1883-90 [12820473.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8677-87 [14647462.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):591-7 [15166262.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):197-205 [15246191.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):475-9 [15197584.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2624-7 [15309707.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1205-11 [15361372.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1983-90 [8934545.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2470-6 [10344760.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):248-53 [15620951.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:11-5 [16382038.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):31-9 [16159682.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):323-8 [16406136.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):385-9 [16443262.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):524-32 [16908128.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):631-5 [17001674.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):617-24 [17001697.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1517-23 [17009165.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7279-83 [17189399.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):272-7 [17174141.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):483-6 [16698957.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):301-5 [17987787.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):268-79 [11425269.001]
  • (PMID = 19309490.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084176-07; United States / NCI NIH HHS / CA / R01 CA084176; United States / NCI NIH HHS / CA / R01 CA084176-07
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS218465; NLM/ PMC2911575
  •  go-up   go-down


68. Zhou S, Xu S, Zhang H, Liu Z, Liang Z, Song X, Jiang Y, Zhao D: [Expression of hepatoma-derived growth factor and its clinical implication in stage I non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Aug 20;10(4):291-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of hepatoma-derived growth factor and its clinical implication in stage I non-small cell lung cancer].
  • The aim of this study is to evaluate the expression of HDGF and its clinical implication in patients who undergone complete resection for stage I non-small cell lung cancer (NSCLC).
  • METHODS: Immunohistochemical technology was applied to detect the expression of HDGF in 118 lung cancer tissues and 30 normal lung tissues as control.
  • HDGF positively staining was seen in all patients, and remarkably higher than that in normal lung tissues (52.23±10.35 vs 156.73±70.95, P < 0.01).
  • Expresson of HDGF was closely related to histological classification, but not to other clinicopathological factors, and the expression of HDGF in adenocarcinoma was much stronger than that in squamous cancers (P=0.001).
  • Univariate analysis and multivariate Cox regression analysis showed that the patients with high HDGF expression had a shorter overall survival and HDGF was a significantly independent predictive factor for patients with stage I NSCLC (RR=1.011, P=0.002).
  • CONCLUSIONS: HDGF may be a promising predictive factor for stage I NSCLC, and the assessment of HDGF may provide new insight on carcinogenesis and development of stage I NSCLC .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122296.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Hjelde H, Sundstrøm S, Ødegård A, Hatlinghus S, Abusland AB, Haaverstad R: [Recurrence and survival after surgical treatment of lung cancer]. Tidsskr Nor Laegeforen; 2010 Jan 14;130(1):25-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence and survival after surgical treatment of lung cancer].
  • BACKGROUND: 2500 new cases of lung cancer are diagnosed in Norway annually.
  • The aim of the study was to review survival and recurrence, and factors which affect survival, in patients operated for lung cancer.
  • MATERIAL AND METHODS: The risk of death and recurrence of disease was assessed retrospectively in patients who had non-small lung cancer and were operated at St. Olavs University Hospital, Trondheim in the period 1994-2001.
  • Adenocarcinoma was the most common histological cancer type and occurred in 57.9 % of women and 39.1 % of the men (p = 0.02).
  • Prognostic factors for survival, estimated by Hazard ratio for death with Cox multiple regression analysis, were sex, age at the time of operation, type of operation, tumour diameter and postoperative N-stage.
  • Early stage lung cancer can be cured with surgical treatment.
  • Our study confirms an increase in the incidence of adenocarcinoma among lung cancer patients during the last decades.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / surgery. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Norway / epidemiology. Registries. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20094119.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


70. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K: Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep; 2005 Jun;13(6):1075-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
  • Recently, HDGF was found to be a mitogen for lung epithelial cells in vitro and in vivo.
  • This suggests that HDGF may play a critical role in the development and progression of lung cancer.
  • We investigated, immunohistochemically, the relationship between HDGF expression and clinicopathological variables, and the prognostic significance of HDGF in 102 patients with completely resected non-small-cell lung cancer (NSCLC: 70 adenocarcinomas and 32 squamous cell carcinomas).
  • Multivariate analysis revealed that HDGF is a significant independent prognostic factor, more powerful than pathological stage.
  • We consider HDGF as a useful prognostic marker for patients with completely resected NSCLC and it may play a critical role in the pathobiology of lung cancer through its mitogenic and angiogenic activities.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Lung Neoplasms / metabolism. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870924.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / hepatoma-derived growth factor
  •  go-up   go-down


71. Satoh Y, Hoshi R, Horai T, Okumura S, Nakagawa K, Ishikawa Y, Miyata S: Association of cytologic micropapillary clusters in cytology samples with lymphatic spread in clinical stage I lung adenocarcinomas. Lung Cancer; 2009 Jun;64(3):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of cytologic micropapillary clusters in cytology samples with lymphatic spread in clinical stage I lung adenocarcinomas.
  • OBJECTIVE: Cytologic micropapillary clusters (MPCs) are round, three-dimensional and cohesive clusters of lung cancer cells with a pseudopapillary configuration.
  • Recently, we demonstrated that MPCs from early stage lung adenocarcinomas can be considered as useful aids to assessing prognosis.
  • We here demonstrate that stage I lung adenocarcinomas found to be positive for MPCs in preoperative cytologic approaches are high risk for lymphatic spread.
  • METHODS: The clinicopathologic characteristics, metastatic status of dissected lymph nodes, vascular infiltration and presence of MPCs in preoperative cytologic specimens in 209 patients with clinical stage I lung adenocarcinomas undergoing complete surgical resection during 2004-2006 were reviewed.
  • RESULTS: Thirty-eight patients (18%) had positive MPC findings; 21 patients with clinical stage IA and 17 with stage IB.
  • In particular, 50% of clinical stage I patients with MPCs demonstrated advance in the postoperative stage of disease.
  • CONCLUSIONS: MPCs may be a manifestation of aggressive behavior, as evidenced by frequent lymph node metastasis, of clinical stage I lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cytological Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027190.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


72. Funakoshi Y, Maeda H, Takeda S, Nojiri T, Kawamura T: Tumor histology affects the accuracy of clinical evaluative staging in primary lung cancer. Lung Cancer; 2010 Nov;70(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor histology affects the accuracy of clinical evaluative staging in primary lung cancer.
  • OBJECTIVE: Pathological examination of lung cancer often reveals a more advanced stage than clinical stage.
  • METHODS: This retrospective study enrolled patients who had undergone major lung resections and systemic lymph node dissections (1990-2004).
  • In total, 483 patients had adenocarcinoma and 225 had squamous cell carcinoma.
  • RESULTS: Clinical and pathologic N-status were significantly different in patients with adenocarcinoma (p<0.0001) but not in those with squamous cell carcinoma.
  • Patients with adenocarcinoma were more likely to be upstaged from clinical N0 disease to pathologic N2 disease than those with squamous cell carcinoma (p = 0.04).
  • Of those patients with adenocarcinoma, surgical procedure, clinical N-status, metastatic pathologic N2 stations and curability were significant prognostic factors.
  • Furthermore, multivariate analysis demonstrated that clinically detectable N2 disease and multiple pathologic N2 stations significantly affected the poorer prognosis in adenocarcinoma.
  • Adenocarcinoma patients with clinically undetectable N2 disease had significantly better 5-year survival than those with clinically detectable N2 disease (p<0.0001), although this was not the case for patients with squamous cell carcinoma (p = 0.81).
  • CONCLUSION: In adenocarcinoma patients with pathologic N2 disease, clinical N-status and metastatic pathologic N2 stations were significant prognostic factors.
  • Adenocarcinoma and squamous cell carcinoma appear to have different tendencies for lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20621386.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


73. Serrano Solares S, Isla Casado D, Vidal Losada MJ, Tobeña Puyal M, Ferrer Pérez AI, Pajares I: Dramatic complete response in patient with lung adenocarcinoma. Clin Transl Oncol; 2009 Dec;11(12):851-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic complete response in patient with lung adenocarcinoma.
  • The poor prognosis of non-small-cell lung cancer (NSCLC) is changing thanks to the constant development of new treatments and the introduction of target therapies, even in stage IV disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):591-8 [19075278.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):753-60 [20038730.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4617-25 [18678835.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • (PMID = 20045793.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


74. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U: Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep; 2008 Jul;20(1):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis.
  • Non-small cell lung cancer (NSCLC) comprises of 75% of all lung cancers.
  • The TF protein concentration was quantified by ELISA in a subset of 11 AC and 9 normal tissue specimens as well as in the plasma of 13 lung cancer patients and 15 healthy controls.
  • AsHTF mRNA expression was significantly lower in patients with stage IA disease compared to patients with higher grade stages, pointing to TF as being a marker of malignancy and metastases.
  • TF protein of lung tumors was significantly increased in AC (p=0.004 vs. controls).
  • TF in plasma was up-regulated in lung cancer patients (334.9+/-95.4 vs. 124.1+/-14.8 pg/ml; p=0.02 vs. controls).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry. Thromboplastin / analysis. Thrombosis / etiology
  • [MeSH-minor] Adenocarcinoma / chemistry. Blotting, Western. Humans. Immunohistochemistry. Neoplasm Metastasis. RNA, Messenger / analysis


75. Kasprzyk M, Dyszkiewicz W, Zwaruń D, Szydlik S, Leśniewska K, Krzyzanowski M: [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)]. Przegl Lek; 2006;63(10):936-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)].
  • The most common pathological cancer type was the squamous cell cancer (24 patients) and adenocarcinoma (17 patients).
  • The majority of the patients were stage IIB (15 patients) and IIIA (14 patients).
  • Significantly higher serum AT level were found in patients with adenocarcinoma as compared to other pathology types.
  • In the group of patients with T3 or T4 stage the following five APPs were significantly elevated: CRP, AGP, alfa-1 ACT, alfa-2 M and Cp.
  • Patients with adenocarcinoma of the lung and regional lymph node metastasis have significantly higher serum levels of AT.
  • AGP is a protein that correlates positively with a more advanced clinical stage, and the extent of the surgical procedure as well as with the higher risk of morbidity.
  • [MeSH-major] Acute-Phase Proteins / analysis. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / blood. alpha 1-Antitrypsin / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Ceruloplasmin / analysis. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Orosomucoid / analysis. Prognosis. alpha 1-Antichymotrypsin / blood. alpha-Macroglobulins


76. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y: Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res; 2008 Dec 15;14(24):8213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.
  • PURPOSE: It is a critical challenge to determine the risk of recurrence in early stage non-small cell lung cancer (NSCLC) patients.
  • EXPERIMENTAL DESIGN: Multiple published microarray data sets were used to evaluate our previously identified lung cancer prognostic gene signature.
  • Expression of the signature genes was further validated with real-time reverse transcription-PCR and Western blot assays of snap-frozen lung cancer tumor tissues.
  • The 35-gene signature further stratified patients with clinical stage 1A diseases into poor prognostic and good prognostic subgroups (P = 0.0007, Kaplan-Meier analysis, log-rank tests).
  • This signature is independent of other prognostic factors for NSCLC, including age, sex, tumor differentiation, tumor grade, and tumor stage.
  • The expression of the signature genes was validated with real-time reverse transcription-PCR analysis of lung cancer tumor specimens.
  • Protein expression of two signature genes, TAL2 and ILF3, was confirmed in lung adenocarcinoma tumors by using Western blot analysis.
  • These two biomarkers showed correlated mRNA and protein overexpression in lung cancer development and progression.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2000 Oct 20;80(2):192-202 [11074587.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):26-31 [11227069.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Genome Biol. 2003;4(4):R27 [12702208.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Aug;29(2):157-62 [12600827.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5360-70 [15064725.001]
  • [Cites] Science. 2004 Oct 22;306(5696):640-3 [15499008.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3875-84 [15492012.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7278-85 [16129846.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Science. 2006 May 26;312(5777):1165-8 [16728629.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Exp Oncol. 2006 Jun;28(2):99-105 [16837898.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Mamm Genome. 2006 Sep;17(9):941-9 [16964442.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(2):229-35 [16932852.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 1:S5 [17430572.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2946-54 [17504995.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • (PMID = 19088038.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084953-050003; United States / NCRR NIH HHS / RR / P20 RR016440; United States / NCRR NIH HHS / RR / P20 RR16440-03; United States / NCI NIH HHS / CA / R01 CA060731; United States / NCI NIH HHS / CA / 5R01CA060731-13; United States / NLM NIH HHS / LM / R01 LM009500; United States / NLM NIH HHS / LM / LM009500-01A2; United States / NCI NIH HHS / CA / U19 CA084953-050003; United States / NCRR NIH HHS / RR / RR016440-08; United States / NLM NIH HHS / LM / R01 LM009500-01A2; United States / NCRR NIH HHS / RR / P20 RR016440-08; United States / NCI NIH HHS / CA / U19 CA084953; United States / NCI NIH HHS / CA / R01 CA154365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78586; NLM/ PMC2605664
  •  go-up   go-down


77. Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, Qiu J, Misek DE, Hinderer R, Tammemagi M, Landi MT, Caporaso N, Pfeiffer R, Edelstein C, Goodman G, Barnett M, Thornquist M, Brenner D, Hanash SM: Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res; 2007 Dec 15;67(24):12000-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer.
  • We have implemented a strategy to identify tumor antigens that induce a humoral immune response in lung cancer based on the analysis of tumor cell proteins.
  • Chromatographically fractionated protein extracts from three lung cancer cell lines were subjected to Western blotting and hybridization with individual sera to determine serum antibody binding.
  • One set consisted of sera from 19 newly diagnosed subjects with lung adenocarcinoma and 19 matched controls.
  • A second independent set consisted of sera from 26 newly diagnosed subjects with lung adenocarcinoma and 24 controls matched for age, gender, and smoking history.
  • Remarkably, significant autoantibody reactivity against 14-3-3 theta was also observed in an analysis of a third set consisting of 18 prediagnostic lung cancer sera collected as part of the Beta-Carotene and Retinol Efficacy Trial cohort study, relative to 19 matched controls (P = 0.0042).
  • A receiver operating characteristic curve constructed with a panel of three proteins consisting of 14-3-3 theta identified in this study, plus annexin 1 and protein gene product 9.5 proteins previously identified as associated with autoantibodies in lung cancer, gave a sensitivity of 55% at 95% specificity (area under the curve, 0.838) in discriminating lung cancer at the preclinical stage from matched controls.
  • [MeSH-major] 14-3-3 Proteins / analysis. Adenocarcinoma / immunology. Antibody Formation. Antigens, Neoplasm / immunology. Autoantibodies / immunology. Biomarkers / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / immunology


78. Hashizume T, Ogura T, Kozawa S, Kobayashi N, Tagawa A, Miyazawa N, Watanuki Y, Takahashi H: [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer]. Gan To Kagaku Ryoho; 2006 Apr;33(4):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
  • BACKGROUND: The objective of this study was to evaluate the efficacy and toxicity of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
  • RESULTS: Median age 68 years, male/female 10/9, stage III/IV 7/12, smoker/non-smoker 12/7, adenocarcinoma/non-adeno 13/6, PS 0/1/2/3/4 0/4/7/5/3.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


79. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L: A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res; 2008 Mar 1;14(5):1355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
  • We have previously shown that the expression of several tissue kallikreins is significantly altered at the transcriptional level in lung cancer.
  • Here, we examined the clinical value of 11 members of the tissue kallikrein family as potential biomarkers for lung cancer diagnosis.
  • EXPERIMENTAL DESIGN: Serum specimens from 51 patients with non-small cell lung cancer (NSCLC) and from 50 healthy volunteers were collected.
  • Expression of KLK11 and KLK12 was positively correlated with stage.
  • CONCLUSIONS: We propose a multiparametric panel of kallikrein markers for lung cancer diagnosis with relatively good accuracy.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Tissue Kallikreins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / blood. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / pathology. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. ROC Curve

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-86366; United States / NCI NIH HHS / CA / P50-CA90388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.35 / Tissue Kallikreins
  •  go-up   go-down


80. Wang W, Shang L, Li X, Wen F, Song W, Li J: [Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Aug 20;10(4):316-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is one of the important treatment methods for advanced non-small cell lung cancer (NSCLC).
  • METHODS: Sixty-four stage IIIB/IV NSCLC patients were treated with docetaxel (75 mg/m² intravenously, on day 1) and carboplatin (AUC=5 intravenously, on day 2).
  • The 1-year survial rate and MST of stage IIIB patients were 44.86% and 15 months, and 39.75% and 12 months respectively in stage IV patients (P=0.0354).
  • There was no significant difference in efficacy between squamous cell carcinoma and adenocarcinoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122302.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res; 2008 Nov 15;14(22):7430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  • We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Tumor of 533 patients with surgically resected NSCLC was used for analysis of stromal and epithelial protein expression by immunohistochemistry (EMT-MET proteins) and Elastica van Gieson histochemical staining (collagen and elastin).
  • RESULTS: Of the 533 patients, 48% had squamous cell carcinoma, 47% adenocarcinoma, and 5% adenosquamous carcinoma.
  • High expression of periostin in either stroma or tumor epithelia, independently scored by two pathologists, correlated with male gender, higher stage, higher pT category, and larger tumor size, and in only stroma with tumor relapse.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010860.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


82. Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M: Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract; 2006 Jun;60(6):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
  • In non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor.
  • Other than stage, many biological markers and many other prognostic factors are studied to define their effects on prognosis of lung cancer.
  • Twelve of 69 cases (17.4%) were stage I, 28 (40.5%) were stage II, 17 were (24.6%) stage IIIA, nine cases were (13.1%) stage IIIB and three cases (4.4%) were stage IV patients.
  • Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients).
  • The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively.
  • The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively.
  • We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy.
  • These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805752.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


83. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Batra SK, Imai K, Yonezawa S: MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer; 2007 Feb;55(2):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma.
  • The mortality of lung cancer remains high, despite improved diagnostic techniques that allow small lung tumors to be detected.
  • In this study, we evaluated the prognostic significance of the tracheal mucin MUC4 by immunohistochemical investigation of the expression profiles of MUC4, ErbB2, p27 and MUC1 in lung adenocarcinoma specimens (non-bronchiolo-alveolar type, < or =3cm) from 185 patients.
  • However, MUC4 expression was found to be unrelated to expression of MUC1, ErbB2 and p27 in small-sized lung adenocarcinomas.
  • In addition, the survival rate of stage IA patients with high MUC4 expression was significantly lower than that of stage IA patients with low MUC4 expression (P<0.05).
  • In conclusion, high MUC4 expression in small-sized lung adenocarcinomas correlates with a short DFI and a poor survival rate.
  • Therefore, MUC4 expression might be a new independent factor for prediction of outcome and indication of poor prognosis in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Lung Neoplasms / metabolism. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126950.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V: Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol; 2009 Sep;4(9):1148-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
  • PATIENTS AND METHODS: Eligible patients had non-small cell lung cancer in stage IIIB (wet) or IV, Karnofsky performance status 100 to 70 (Eastern Cooperative Oncology Group 0-2), measurable disease, were chemonaïve and fulfilled the standard criteria for chemotherapy.
  • Adenocarcinoma (53.9%) was the predominant histologic type; 92% of patients were in stage IV.
  • The two groups were balanced for prognostic factors; however, group A had fewer patients with significant weight loss and no patient with lung cancer as a second malignancy or after radiotherapy for brain metastases.
  • CONCLUSION: In the treatment of advanced non-small cell lung cancer, gemcitabine in low dose in prolonged infusion in combination with cisplatin has low toxicity and has activity comparable with gemcitabine in higher dose in standard brief infusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546818.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE: A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res; 2006 Apr 15;12(8):2484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.
  • Occult lymph node metastasis (micrometastasis) is a good prognostic indicator in non-small cell lung cancer (NSCLC) and could be used to direct adjuvant chemotherapy in stage I patients.
  • PVA and SFTPB are particularly powerful in tumors of squamous and adenocarcinoma histologies, respectively, whereas TACSTD1 is a good general marker for NSCLC metastasis.
  • Long-term follow-up will determine the clinical relevance of these findings.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Pathol. 2001 Jul;194(3):298-302 [11439361.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):324-9 [14553843.001]
  • [Cites] Clin Lung Cancer. 2004 Jan;5(4):214-25 [14967073.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2671-80 [15226334.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [9338638.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):19-24 [10458213.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1099-109 [15709177.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2147-56 [15781625.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s [16000607.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • (PMID = 16638856.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094059-04; United States / NCI NIH HHS / CA / R01 CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059; United States / NCI NIH HHS / CA / CA094059-03; United States / NCI NIH HHS / CA / R01 CA094059-01; United States / NCI NIH HHS / CA / R01 CA090665; United States / NCI NIH HHS / CA / R01 CA094059-03; United States / NCI NIH HHS / CA / R01CA90665; United States / NCI NIH HHS / CA / CA094059-02; United States / NCI NIH HHS / CA / CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059-02; United States / NCI NIH HHS / CA / R01 CA094059-04; United States / NCI NIH HHS / CA / CA094059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DSG3 protein, human; 0 / Desmoglein 3; 0 / EPCAM protein, human; 0 / Pulmonary Surfactant-Associated Protein B
  • [Other-IDs] NLM/ NIHMS24707; NLM/ PMC1933488
  •  go-up   go-down


86. Takahashi Y, Kiba T, Yamaguchi K, Saitou Y, Nishio K, Iguch M, Motoo Y: [A case undergoing repeated anaphylactic shock after systemic administration of vinorelbine]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2321-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We here describe a 49-year-old man who suffered repeated anaphylactic shock after systemic chemotherapy with vinorelbine for stage IV left lung adenocarcinoma (S1+2).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Food Hypersensitivity / etiology. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Pistacia / adverse effects

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


87. Kanematsu T, Hanibuchi M, Tomimoto H, Sakiyakma S, Kenzaki K, Kondo K, Bando H, Haku T, Yoneda K, Hirose T, Toyoda Y, Goto H, Sakaguchi S, Kinoshita K, Azuma M, Kakiuchi S, Kishi J, Azuma M, Tada H, Sumitomo M, Nishioka Y, Yano S, Sone S: Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan. J Med Invest; 2010 Aug;57(3-4):326-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan.
  • Lung cancer is the leading cause of malignancy-related death worldwide.
  • In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan.
  • Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study.
  • One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%).
  • Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively.
  • These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection.
  • [MeSH-major] Lung Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / epidemiology. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Risk Factors. Smoking / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847534.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Su YJ, Xu F, Yu JP, Yue DS, Ren XB, Wang CL: Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features. Chin Med J (Engl); 2010 Aug;123(16):2215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features.
  • This study aimed to determine the expression of the two indices of the family, S100A8 and S100A9, in lung cancer tissues and normal lung tissues and its correlation with clinical features.
  • METHODS: A total of 60 cases with a variety of clinical data that were diagnosed with different histological subtypes of lung cancer were investigated.
  • Semi-quantitative reverse transcriptase-PCR (Sq-Rt-PCR) and immunohistochemical staining of cancer, adjacent and peripheral lung tissues were executed to distinguish the expression patterns of S100A8 and S100A9 and to further clarify their correlation with clinical features.
  • RESULTS: Immunohistochemical staining of both proteins showed a significant up-regulation in lung cancer tissue (S100A8, S100A9, P<0.0001), and PCR revealed that the levels of S100A8 and S100A9 expression were significantly higher in lung cancer tissues (S100A8 P=0.002/0.004; S100A9 P=0.022/0.026).
  • The higher expression was found to be correlated with the clinical characteristics of adenocarcinoma, inflammation and stage IV lesion.
  • CONCLUSIONS: S100A8, S100A9 up-regulation was found in the lung adenocarcinoma and end stage lung cancer tissue, the correlation of which with their higher expression in inflammatory lung tissues may indicate the collaborative effect of inflammation on the progression of cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Calgranulin A / metabolism. Calgranulin B / metabolism. Inflammation / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819668.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Calgranulin A; 0 / Calgranulin B
  •  go-up   go-down


89. Guldur ME, Kibar Y, Deniz H, Bakir K: Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. Pathol Oncol Res; 2010 Mar;16(1):55-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas.
  • This study was performed to compare osteopontin (OPN), beta-catenin and heterogeneous nuclear ribonucleoprotein B1 (hnRNP B1) immunreactivities in small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC).
  • Correlation of these three antibodies with grade and clinicopathologic stage of the tumor in NSCLC was also investigated.
  • Twenty-nine SCLC, 6 large cell carcinoma, 36 adenocarcinoma and 30 squamous cell carcinoma (SCC), totally 101 cases, were included in this study.
  • Neither grade nor stage of NSCLC was correlated with osteopontin, beta-catenin or hnRNP B1 immunreactivity.
  • This may be helpful in small lung biopsies where morphology is obscured by crush artifacts.
  • [MeSH-major] Biomarkers, Tumor / analysis. Heterogeneous-Nuclear Ribonucleoprotein Group A-B / biosynthesis. Lung Neoplasms / metabolism. Osteopontin / biosynthesis. beta Catenin / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1896-902 [11280744.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):179-86 [12871781.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10760-6 [8631886.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4789-96 [11156236.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Sep;24(3):441-9 [12965318.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6459-65 [16166420.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):215-22 [11520606.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):391-5 [11328840.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1588-96 [15014008.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):395-402 [17067748.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4646-52 [16000556.001]
  • [Cites] Pathol Res Pract. 2006;202(9):639-50 [16843618.001]
  • (PMID = 19609729.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / beta Catenin; 0 / hnRNP A2; 106441-73-0 / Osteopontin
  •  go-up   go-down


90. Parissis H, Leotsinidis M, Hughes A, McGovern E, Luke D, Young V: Comparative analysis and outcomes of sleeve resection versus pneumonectomy. Asian Cardiovasc Thorac Ann; 2009 Apr;17(2):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To compare the outcome of sleeve resection or complex sleeve resection versus (Vs) pneumonectomy for lung cancer in a single unit.
  • Between 1998 and 2006, 664 lung resections were carried out.
  • The survival for the complex SR was not influenced by the complexity of the procedure but from the TNM stage of each individual case.
  • Multivariate analysis of risk factors affecting survival after surgery showed: male sex Hazard ratio (HR) 1.19, 0.63-2.27(95%CI), Age >63 1.38(HR), 0.78-2.48, Pneumonectomy 1.78(HR), 0.92-3.46 and stage III 4.44(HR), 1.94-10.16(95% CI).
  • For comparative stages survival appears to be better after sleeves, moreover male sex, sleeve resection, age younger that 63 and early TNM stage are positive predictors for survival.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy. Pulmonary Surgical Procedures

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592550.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


91. Liu H, Zhang T, Li X, Huang J, Wu B, Huang X, Zhou Y, Zhu J, Hou J: Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci; 2008 Nov;99(11):2185-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
  • The present study assessed the prognostic and predictive value of MMP-7 in tumors of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.
  • In total, 159 patients with stage III and IV NSCLC were retrospectively enrolled.
  • MMP-7 status was correlated inversely with response to chemotherapy in overall patients (response rates, 20.0% and 35.8%, for patients with high-MMP-7 and low-MMP-7 tumors, respectively, P = 0.036), especially in adenocarcinoma (P = 0.021), but not in patients with squamous cell carcinomas (P = 0.373).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Matrix Metalloproteinase 7 / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


92. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer; 2005 Apr 15;103(8):1676-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
  • Changes in their expression levels have been observed in various tumor types, including lung carcinoma.
  • However, their clinical significance and their prognostic importance in the progression of nonsmall cell lung carcinoma (NSCLC) remain to be specified.
  • Expression levels of MMPs and TIMPs were evaluated using Northern blot analysis in these NSCLC tissue samples and in 39 matched samples of normal lung tissue.
  • MMP-1 tumor expression was correlated significantly with the evolution of lymph node status and tumor-lymph node-metastasis (TNM) stage.
  • In contrast, MMP-9 tumor expression was correlated significantly with increased T stage.
  • TIMP-1 overexpression was an independent predictor of worse survival in patients with NSCLC that was not associated with other prognosis factors, such as TNM stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Northern. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Disease Progression. Humans. Lung / metabolism. Lung / pathology. Lymphatic Metastasis. Matrix Metalloproteinase 1 / genetics. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Rate. Tissue Inhibitor of Metalloproteinase-2 / genetics. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15754326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


93. Kida Y, Maeshima E, Furukawa K, Ichikawa T, Goda M, Ichinose M: A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol; 2007;17(3):262-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal computer tomography findings revealed a pancreatic-tail tumor and multiple liver nodules, diagnosed as primary pancreatic adenocarcinoma with multiple liver metastasis.
  • The stage of the pancreatic cancer was IV, and curative surgery of the tumor was not indicated.
  • If a high level of KL-6 is found without the increasing activity of lung disease containing interstitial pneumonia in PM patients, examination for the internal malignancies including pancreatic cancer should be performed, although cases of PM with a significantly high level of KL-6 associated with pancreatic cancer are rare.


94. Mao YS, Zhang DC, Zhang HT, Sun YT, Zhao XH, Liu XY, Wei GL, Liu F: [Mediastinal lymph nodes micro-metastases in patients with clinical stage I-II lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):160-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal lymph nodes micro-metastases in patients with clinical stage I-II lung cancer].
  • OBJECTIVE: To investigate micro-metastasis in mediastinal lymph nodes (mLN) of patients with clinical stage I approximately II lung cancer and its clinical significance.
  • METHODS: A total of 181 mLN from 32 lung cancer patients in clinical stage I approximately II were collected during operation and their frozen sections at two different levels were examined immunohistochemically (IHC) with an anti-epithelial cell monoclonal antibody Ber-Ep4.
  • Underestimation of the extent of mLN metastasis by cTNM and/or pTNM stagings frequently exists in patients with clinically early lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946566.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Ber-EP4 monoclonal antibody
  •  go-up   go-down


95. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol; 2006 Apr 10;24(11):1679-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
  • PURPOSE: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers.
  • METHODS: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms.
  • Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features.
  • While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage.
  • CONCLUSION: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification.
  • Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Epidermal Growth Factor / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Molecular Biology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


96. Dong QM, Zheng WH, He YJ: [Comparison of the clinicopathological characteristics of colorectal cancer between elderly and young patients]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep;30(9):2128-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The elderly patients were more likely to have stage II and III tumors than the middle-aged and young patients, having also significantly higher incidences of such complications as heart and lung diseases upon diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855269.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


97. Foeglé J, Hédelin G, Lebitasy MP, Purohit A, Velten M, Quoix E: Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol; 2007 Jun;2(6):466-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997.
  • INTRODUCTION: The literature suggests that lung cancer may represent a different disease in women compared with men and that gender specificities have been reported mostly in clinical trials patients.
  • METHODS: We conducted a retrospective, population-based study of a sample of 1738 patients diagnosed with a non-small cell lung cancer (NSCLC) in the department of Bas-Rhin (northeastern France) between 1982 and 1997.
  • Our study aimed to describe symptoms at presentation, stage, histological distribution, treatment modalities, and survival, according to sex.
  • Adenocarcinoma predominated in women (54.4%), whereas squamous cell carcinoma predominated in men (65.9%).
  • Treatment also differed: in resectable disease, fewer pneumonectomies were performed in women; in locally advanced disease, the mean doses of thoracic irradiation were significantly lower in women (48.0 grays versus 55.5 grays); in metastatic-stage disease, fewer women received platin-based chemotherapy, but this difference was not significant.
  • CONCLUSIONS: This study emphasizes gender differences in smoking exposure, presentation (stage, histological subtype), and diagnostic and therapeutic management of NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545840.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar SY, Fletcher RH: Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol; 2010 Feb 1;28(4):620-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.
  • PURPOSE: To describe chemotherapy use and adverse events (AEs) for advanced-stage, non-small-cell lung cancer (NSCLC) in community practice, including descriptions according to variation by age.
  • Using logistic regression, we assessed the association between age and chemotherapy; with Poisson regression, we estimated event rate ratios and adjusted the analysis for age, sex, ethnicity, radiation therapy, stage, histology, and presence and grade of 27 comorbidities.
  • RESULTS: Of 1,371 patients, 58% (95% CI, 55% to 61%) received chemotherapy and 35% (95% CI, 32% to 38%) had AEs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] Chest. 2000 May;117(5):1239-46 [10807806.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:84 [18939982.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1064-70 [11181670.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] Biometrics. 1999 Jun;55(2):652-9 [11318229.001]
  • [Cites] Lung Cancer. 2001 Sep;33 Suppl 1:S115-20 [11576716.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):779-88 [12910523.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2992-6 [15284250.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3261-8 [15310770.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):61-76 [15364134.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Lung Cancer. 1995 Dec;13(3):235-52 [8719064.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1930-7 [9806651.001]
  • [Cites] Lung Cancer. 1998 Aug;21(2):105-13 [9829544.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4971-8 [15611512.001]
  • [Cites] Chest. 2005 Aug;128(2):947-57 [16100191.001]
  • [Cites] Intern Med J. 2006 Apr;36(4):216-20 [16640737.001]
  • [Cites] Support Care Cancer. 2006 Aug;14(8):837-48 [16482448.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5570-7 [18065729.001]
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):523-6 [20038720.001]
  • [ErratumIn] J Clin Oncol. 2010 May 1;28(13):2314
  • (PMID = 20038726.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / AHRQ HHS / HS / 5 U18 HS016094; United States / PHS HHS / / U01 A093326; United States / NCI NIH HHS / CA / U01 CA093329; United States / NCI NIH HHS / CA / U01 CA093348; United States / NCI NIH HHS / CA / U01 CA093324; United States / AHRQ HHS / HS / U18 HS016094; United States / NCI NIH HHS / CA / U01 CA093344; United States / NCI NIH HHS / CA / U01 CA093332; United States / NCI NIH HHS / CA / U01 CA01013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2815997
  •  go-up   go-down


99. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, Stewart AK: Patterns of surgical care of lung cancer patients. Ann Thorac Surg; 2005 Dec;80(6):2051-6; discussion 2056
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of surgical care of lung cancer patients.
  • BACKGROUND: This survey was performed to determine the patterns of surgical care provided patients with non-small cell lung carcinoma (NSCLC).
  • Of these patients, 59.5% were in stage I, 17.5% in stage II, 17.0% in stage III, and 6.0% in stage IV.
  • Tumor characteristics: squamous 28%, adenocarcinoma 37.6%, other 34.4%.
  • (1) Patients being operated for NSCLC are elderly with significant comorbid conditions. (2) More patients than previously are female and have adenocarcinoma. (3) Mediastinoscopy is infrequently performed and lymph nodes are biopsied in less than 50% of them. (4) Lobectomy is the most common operation, and positive surgical margins are too frequent. (5) Operative mortality is reasonable but transfusion is a marker for increased risk and outcomes are superior in high-volume hospitals. (6) Hospitals with higher volume had fewer perioperative deaths.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery


100. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R: Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res; 2008 Aug 15;68(16):6822-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
  • Herein, using transgenic adenocarcinoma of the mouse prostate (TRAMP) model, we assessed the "stage-specific" efficacy of silibinin feeding against prostate cancer (PCa) initiation, progression, angiogenesis and metastasis, and associated molecular events involved in silibinin effects during these stages.
  • Male TRAMP mice starting at ages 4, 12, 20, and 30 weeks of age were fed with control or 1% silibinin-supplemented diet for 8 to 15 weeks in stage-specific manners.
  • Together, these findings are both novel and highly significant in establishing the dual efficacy of silibinin where it inhibits progression of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage metastasis.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15809-14 [9861052.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2104-15 [16208706.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Nov;5(6):603-12 [16305482.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Aug;20(4):831-43 [16861117.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1862-74 [17043660.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(6):1082-8 [17416542.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5976-82 [17575168.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):475-83 [17691907.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S9-S13 [17644117.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Food Chem Toxicol. 2008 Apr;46(4):1334-45 [17919802.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6777-82 [11559550.001]
  • [Cites] Cancer Invest. 2002;20(1):139-53 [11852996.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [14504208.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):272-80 [14663466.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4325-6 [16179603.001]
  • (PMID = 18701508.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112304-04; United States / NCI NIH HHS / CA / R01 CA112304; United States / NCI NIH HHS / CA / R01 CA112304-04; United States / NCI NIH HHS / CA / R01CA102514; United States / NCI NIH HHS / CA / R01 CA102514
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Silymarin; 0 / Vascular Endothelial Growth Factor A; 4RKY41TBTF / silybin; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ NIHMS55332; NLM/ PMC2587411
  •  go-up   go-down






Advertisement